April 25–30 / 25–30 avril

ANNUAL CONFERENCE
CONFÉRENCE ANNUELLE
AMMI Canada – CACMID

Where Canada’s Experts in Clinical Microbiology and Infectious Diseases Will Meet VIRTUALLY!

FINAL PROGRAM
PROGRAMME FINAL

WWW.AMMI.CA
WWW.CACMID.CA
WELCOME

On behalf of the Association of Medical Microbiology and Infectious Disease Canada and the Canadian Association for Clinical Microbiology and Infectious Diseases we would like to welcome you to the 17th annual conjoint meeting on the prevention, diagnosis, and treatment of infectious diseases. We are excited to be offering the event in a fully virtual format this year! From interactive scientific sessions to posters and an exhibit hall, this will be an excellent opportunity to learn and connect in an engaging online experience.

The Central and Scientific Planning Committees have put in long hours to produce an exceptional virtual program for attendees this year. There will be on-demand poster sessions and live oral presentations to showcase the research done by our students, residents, fellows, and colleagues, with awards for the best student abstracts presented at the conference. The state-of-the-art clinical lectures will cover up-to-date information on COVID-19 vaccines and immunity, the use of bacteriophages as antimicrobial therapies, zoonoses, and how artificial intelligence can be used to detect and control epidemics. The plenaries will focus on COVID-19, clinical controversies in infectious diseases and diagnostic microbiology, as well as hot topics in infection control, diagnostic microbiology, and both adult and paediatric infectious diseases. The Scientific Planning Committee has also co-developed integrated symposia and workshops for delegates to attend.

Lastly, excellent Trainees’ Day interactive sessions are planned with ample opportunity for networking.

We would like to acknowledge the generous and continued support from our industry partners, sponsors, and exhibitors, which has allowed us to preserve our high-quality meeting. We encourage you to virtually walk through the exhibit hall, expand your network, and see what’s new and exciting.

COVID-19 has put our professions at the forefront, and we are excited to bring together Canada’s experts in this unique setting to not only highlight excellent COVID-19 research, but also other hot topics in clinical microbiology and infectious diseases.

AMMI Canada and CACMID are proud of the ongoing collaboration leading to this high-quality annual meeting. On behalf of the Central and Scientific Planning Committees, we look forward to seeing you online and providing you with not only an educational event, but also opportunities for you to have fun, network, and socialize with your colleagues.

Sarah Forgie
President, AMMI Canada

Tanis Dingle
President, CACMID
Au nom de l'Association pour la microbiologie médicale et l'Infectiologie Canada et de l'Association canadienne de microbiologie clinique et des maladies infectieuses, nous vous souhaitons la bienvenue à la 17e conférence annuelle conjointe sur la prévention, le diagnostic et le traitement des maladies infectieuses. Nous sommes heureux de tenir l'événement sous forme virtuelle cette année. À partir de séances scientifiques interactives jusqu’aux présentations par affiches en passant par la salle d'exposition, ce sera une excellente occasion de s'instruire et d'établir des liens dans une expérience en ligne engageante.

Les comités de planification générale et scientifique ont consacré de longues heures à la mise au point d’un programme exceptionnel. Il y aura diverses présentations par affiches et orales d'études effectuées par nos étudiants, résidents, boursiers et collègues, ainsi que la remise de prix pour les meilleurs résumés d'étudiants présentés à la conférence. Les exposés cliniques de pointe donneront des renseignements à jour sur les vaccins contre la COVID-19 et l'immunité, l'utilisation de bactériophages comme traitements antimicrobiens, les zoonoses, et comment l'intelligence artificielle peut servir à détecter et contrôler les épidémies. Les séances plénières porteront sur la COVID-19, les controverses cliniques dans les maladies infectieuses et la microbiologie diagnostique, ainsi que sur des sujets chauds dans le contrôle de l'infection, la microbiologie diagnostique et les maladies infectieuses chez les adultes et les enfants. Le Comité scientifique a également co-élaboré des symposiums et ateliers intégrés pour les participants. Enfin, les excellentes séances interactives de la Journée des stagiaires constitueront d'excellentes occasions de réseautage.

Nous aimerions souligner le soutien généreux et continu de nos partenaires du secteur, de nos commanditaires et de nos exposants qui nous a permis de continuer à offrir cette conférence de grand calibre. Nous vous encourageons à visiter le salon des exposants, à élargir votre réseau et à découvrir ce qu'il y a de nouveau et d'intéressant.

La COVID-19 a mis nos professions à l'avant-garde et nous sommes heureux d'apporter des experts canadiens à cet événement unique non seulement pour mettre en évidence l'excellente recherche sur la COVID-19 mais aussi d'autres sujets chauds en microbiologie clinique et maladies infectieuses.

L’AMMI Canada et la CACMID sont fiers de cette collaboration continue qui conduit à cette conférence de grande qualité. Au nom des comités de planification générale et scientifique, nous vous recevrons avec plaisir en ligne pour vous offrir non seulement un événement éducatif, mais de nombreuses possibilités de vous distraire, de réseauter et de socialiser avec vos collègues.

Sarah Forgie
Présidente, AMMI Canada
Tanis Dingle
Présidente, CACMID
CONTENTS

Welcome 2
Bienvenue 3
How to Use the Virtual Platform 4
Collaborating Societies 5
Are You a Member? 6

COMMITEES, AND COUNCILS
AMMI Canada Council 7
CACMID Board 7
Central Planning Committee (CPC) 7
Scientific Planning Committee (SPC) 8
Sponsorship Committee 8
Abstract Review Committee 8

Accreditation 9
CanMeds 9

PROGRAM
Sunday, April 25 10
Monday, April 26 11
Tuesday, April 27 12
Wednesday, April 28 16
Thursday, April 29 18
Friday, April 30 19

Poster and Oral Awards 20
Save the date! 21
Speaker Biographies 22
E-Posters 28
Student E-Posters 38
Author Index 44
Conflict of Interest Declarations 50
Industry co-developed presentations 53

UNACCREDITED PRESENTATIONS
Unaccredited Learning Activities 55
Exhibit Hall 60
Sponsors 61
General Information 61
The 2021 AMMI Canada – CACMID Annual Conference looks different this year. We will be meeting virtually on the vFairs platform rather than in person.

Tips to help you get started and to ensure you have the best possible experience:

- Chrome, Firefox and Safari are the best browsers for video streaming the vFairs platform. **The platform does not respond well to Explorer**
- Downloading the most current version of Zoom will make the virtual experience more optimal

Once you are registered, visit [www.ammicanadacacmid2021.vfairs.com](http://www.ammicanadacacmid2021.vfairs.com) and login using the email address you registered with

Once you are logged in, you will be brought into the 2021 annual conference lobby. From the lobby you have access to and are able to experience all the annual conference has to offer:
- 3 auditoriums that will host the live and on demand (recorded) dynamic program,
- 2 poster halls,
- An interactive Exhibit Hall that allows for 1:1 video interaction with industry partners,
- Networking lounges so you can catch up with friends and colleagues and,
- Gamification for those with a little competitive nature in them.

If you experience technical difficulties or have any questions, stop by the Information Desk in the lobby or email ammicanadacacmid@getvfairs.io or meetings@ammi.ca.
OBJECTIVES

The AMMI Canada – CACMID Annual Conference provides an interactive venue where experts in the fields of diagnostic microbiology, antimicrobial stewardship, infectious diseases, infection prevention and control, and public health meet. The conference attracts attendees from across Canada and internationally. As in previous years, the 2021 conference will provide updates on a variety of topics to a diverse audience of clinicians, microbiologists, laboratory technologists, public health professionals, infection prevention and control practitioners, students and residents. The one difference this year is that the full conference will be virtual given COVID-19.

In addition to the pre-meeting Trainees’ Day, the program will offer plenary sessions, state of the art clinical lectures, integrated symposia, short oral presentations, poster presentations and workshops. The Interactive Clinical Vignettes and the Incubator will be on hiatus in 2021 and will return in 2022. The 2021 meeting will be a chance for attendees to showcase their research as well as get up to speed with the latest in the areas of microbiology, infection control, adult and paediatric infectious diseases and related subjects. Dynamic expert speakers will be invited from across North America to ensure another exciting meeting.

In addition to the scientific component, the meeting will provide ample opportunity for attendees to network, exchange ideas, and reconnect with colleagues all within the comfort of your own home or office!

ARE YOU A MEMBER?

To join AMMI Canada please contact:
Terence Wuerz, MD, MSc, FRCPC
Secretary, AMMI Canada
c/o AMMI Canada Secretariat
192 Bank Street
Ottawa, ON K2P 1W8
Toll-free: 1 (866) 467-1215
Tel.: (613) 260-3233 ext. 103
Fax: (613) 260-3235
Email: membership@ammi.ca
For more information on AMMI Canada visit:
www.ammi.ca

To join CACMID please contact:
Ramzi Fattouh, PhD, FCCM
Secretary, CACMID
c/o Laboratory Medicine
St. Michael’s Hospital
30 Bond St., CC Rm 2-040
Toronto, ON M5B 1W8
Email: info@cacmid.ca
For more information on CACMID visit:
www.cacmid.ca
AMMI Canada Council

President
Sarah Forgie, Edmonton, AB

President Elect
Deborah Yamamura, Hamilton, ON

Past President
Todd Hatchette, Halifax, NS

Treasurer
Andrew Simor, Toronto, ON

Secretary
Terence Wuerz, Winnipeg, MB

MM – Section Chair
Philippe Lagacé-Wiens, Winnipeg, MB

ID – Section Chair
Shariq Haider, Hamilton, ON

Members of Council
Isabelle Chiu, Edmonton, AB
Susy Hota, Toronto, ON
Yves Longtin, Montréal, QC
LeeAnne Luft, Kelowna, BC
Kelly MacDonald, Winnipeg, MB
Karina Top, Halifax, NS

CACMID Board

President
Tanis Dingle, Edmonton, AB

Vice President
Agatha Jassem, Vancouver, BC

Past President/Treasurer
Carmen Charlton, Edmonton, AB

Secretary
Ramzi Fattouh, Toronto, ON

Meeting Secretary/Councillor
Chris Lowe, Vancouver, BC

Scientific Planning Committee Co-Chair
Rob Kozak, Toronto, ON

Webmaster
Vanessa Tran, Toronto, ON

Councillor
Danielle Brabant-Kirwan, Sudbury, ON

Councillor
Esther Nagal, Toronto, ON

Councillor
Samir Patel, Toronto, ON

Councillor
Valentina Russell, Winnipeg, MB

Councillor
Prameet Sheth, Kingston, ON

Central Planning Committee (CPC)

Co-Chairs
Tanis Dingle
Sarah Forgie

Scientific Planning Committee Co-Chairs
Robert Kozak
Susan Poutanen
Christine Turenne

Co-Treasurers
Carmen L. Charlton
Andrew Simor

Sponsorship Committee Co-Chairs
Jeff Fuller
Shariq Haider

Abstract Co-Chairs
Christian Lavallée
Christopher Lowe

Committee Members
Todd Hatchette
Agatha Jassem
Scientific Planning Committee (SPC)

**Co-Chairs**
Robert Kozak  
Susan Poutanen  
Christine Turenne

**Committee Members**
Danielle Brabant-Kirwan  
Marthe Charles  
William Connors  
Melanie Di Quinzio  
Ramzi Fattouh  
Catherine Hogan  
Agatha Jassem  
Jennie Johnstone  
Farhan Khan  
Philippe Lagacé-Wiens  
Christian Lavallée  
Christopher Lowe  
Kathy Malejczyk  
Esther Nagai  
Samir Patel  
David Patrick  
Glenn Patriquin  
Peter Pieroni  
Earl Rubin  
Valentina Russell  
Joanne Salmon  
Yoko Schreiber  
Prameet M. Sheth  
Vanessa Tran

Sponsorship Committee

**Co-Chairs**
Jeff Fuller  
Shariq Haider

**Committee Members**
Danielle Brabant-Kirwan  
Marthe Charles  
William Connors  
Melanie Di Quinzio  
Ramzi Fattouh  
Catherine Hogan  
Agatha Jassem  
Jennie Johnstone  
Farhan Khan  
Philippe Lagacé-Wiens  
Christian Lavallée  
Christopher Lowe  
Kathy Malejczyk  
Esther Nagai  
Samir Patel  
David Patrick  
Glenn Patriquin  
Peter Pieroni  
Earl Rubin  
Valentina Russell  
Joanne Salmon  
Yoko Schreiber  
Prameet M. Sheth  
Vanessa Tran

Abstract Review Committee

**Co-Chairs**
Christian Lavallée  
Christopher Lowe

**Committee Members**
Andrée-Anne Boisvert  
Danielle Brabant-Kirwan  
Julie Carson  
Vikas Chaubey  
Jeannette Comeau  
William Connors  
Peter Daley  
Meghan Dey  
Tanis Dingle  
Steven J. Drews  
Eric Eckbo  
Chelsey Ellis  
Ramzi Fattouh  
Jeff Fuller  
Simon Grandjean-Lapierre  
Daniel B. Gregson  
David Harris  
Catherine Hogan  
B. Lynn Johnston  
Imane Jroundi  
Robert Kozak  
Jérôme Laflamme  
Clayton MacDonald  
Nancy Matic  
Vanessa Meier-Stephenson  
Muhammad Morshed  
Esther Nagai  
Conor O’Neil  
Peter Pieroni  
Prameet Sheth  
Christine Turenne  
Bing Wang  
Deborah Yamamura
canmeds

CanMEDS is a framework that identifies and describes the abilities physicians require to effectively meet the health care needs of the people they serve. These abilities are grouped thematically under seven roles. A competent physician seamlessly integrates the competencies of all seven CanMEDS Roles. CanMEDS Roles have been identified for each Plenary and State of the Art (START) Clinical Lecture using the following symbols:

Collaborator (CL)
Communicator (CM)
Health Advocate (HA)
Leader (LE)
Medical Expert (ME)
Professional (PR)
Scholar (SC)


accréditation

For specialists certified with the Royal College of Physicians and Surgeons of Canada (RCPSC): The AMMI Canada - CACMID Annual Conference is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. You may claim a maximum of 20.75 hours.

A. Mainport – Transfer of Hours

The Royal College of Physicians and Surgeons of Canada allows for attendance data of Section 1, Group Learning Activities to be transferred directly into participants’ MAINPORT Transfer of Hours. Please indicate your RCPSC ID Number when registering.

B. For specialists certified with the American Medical Association (AMA): Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credits to AMA credits can be found at www.ama-assn.org/go/internationalcme. Please indicate your AMA ID Number when registering.

C. For Fellows and Specialists of the Canadian College of Microbiologists and Diplomats of the American Board of Medical Microbiology: The Canada College of Microbiologists (CCM) accredits the AMMI Canada – CACMID Annual Conference for CE credits. Certificates of continuing education activity are available through the CCM for documentation of attendance and maintenance of certification. A one-hour educational activity is equivalent to one CE credit. Program evaluation forms and record of CE activity can be obtained and returned, once completed, by email to the FCCM co-chair (hadam@shared-healthmb.ca) following the conference.

The AMMI Canada Education Committee Chair, Dr. Joanne Salmon, is responsible for ensuring that the AMMI Canada - CACMID Annual Conference is compliant with the Royal College National Standard for Support of Accredited CPD Activities.
PROGRAM
(all times indicated in Canadian Eastern time zone)

Sunday, April 25

On Demand Poster Viewing
On Demand Exhibit Hall

12:00 – 16:30 Trainees’ Day
Auditorium: Main Auditorium
Moderator: Farhan Khan (Halifax, NS)
12:00 – 12:10 Welcome, Introductions and Overview
Speaker: Robert Kozak (Toronto, ON)
By the end of this session, participants should be able to:
• Understand the current grant landscape and how to leverage your skills when applying
• Learn my process for preparing for and writing a grant
• Appreciate the top 3 things I've learned from my grant successes and failures

12:10 – 12:40 It's a Game of Grantsmanship, and Your Ship Just Came In
Speaker: Robert Kozak (Toronto, ON)
By the end of this session, participants should be able to:
• Describe the formats of the final examinations in Infectious Diseases, Medical Microbiology, and Clinical Microbiology
• Identify strategies and resources for exam preparation
• Begin developing a study plan in preparation for writing your exam

12:40 – 13:10 Interactive Break Out Sessions

13:10 – 13:40 Navigating the Real World to Paradise Island!
Speaker: Yoko Schreiber (Sioux Lookout, ON)
By the end of this session, participants should be able to:
• Recognize the many possible work applications and opportunities
• Explore strategies to identify and land your ideal job (including CVs and interviews)
• Acquire some personal tips for creating balance

13:45 – 14:15 Interactive Break Out Sessions

14:15 – 14:25 Health Break

14:25 – 14:55 You can do this! Prepping for Exams in ID, Med Micro, and Clin Micro
Speaker: Glenn Patriquin (Halifax, NS)
By the end of this session, participants should be able to:
• Describe the formats of the final examinations in Infectious Diseases, Medical Microbiology, and Clinical Microbiology
• Identify strategies and resources for exam preparation
• Begin developing a study plan in preparation for writing your exam

14:55 – 15:25 Interactive Break Out Sessions

15:30 – 15:40 Wrap Up and Closing Remarks

15:40 – 16:30 Trainees’ Day Networking Lounge
Following Trainees’ Day, you are invited to join the Trainees’ Day Networking Lounge, to meet, mingle and catch up virtually with fellow trainees, speakers and members of the AMMI Canada and CACMID boards.
On Demand Poster Viewing
On Demand Exhibit Hall
10:15 - 11:15 The Influenza Vaccine (R)Evolution
Auditorium: Co-Developed Presentations
Moderator: Philippe Lagacé-Wiens (Winnipeg, MB)
Speaker: Matthew Miller (Hamilton, ON)
By the end of the session the participants will be able to:
• Outline the main factors that impact annual influenza vaccine effectiveness

11:30 – 14:00 Plenary: COVID-19 – What We Know, What We Don’t Know
Auditorium: Main Auditorium
Moderators: Robert Kozak (Toronto, ON)  
Susan Poutanen (Toronto, ON)
11:30 – 11:35 Welcome Remarks and Introduction
11:35 – 11:55 Where Have We Been and Where Are We Going? – Lessons Learned from a National Perspective
Speaker: Theresa Tam (Ottawa, ON)
By the end of this session, participants should be able to:
• Summarize where we have been and where we are going regarding the national response to COVID-19
• Define lessons learned from Canada’s response to date
• Describe Canada’s approach to domestic manufacturing of vaccines and personal protective equipment
12:00 – 12:30 What’s Hot in Diagnostics, Genomics, and Serology
Speaker: Mel Krajden (Vancouver, BC)
By the end of this session, participants should be able to:
• Summarize COVID-19 diagnostic tools: NAT and antigen detection, genomics, and serology
• Define optimal use cases and specimen types for different COVID-19 diagnostic modalities

Illustrate the usefulness of rapid sequencing in the response to COVID-19
12:35 – 13:05 What’s Hot in Transmission/Public Health/Infection Control
Speaker: Dominik Mertz (Hamilton, ON)
By the end of this session, participants should be able to:
• Review the science regarding SARS-CoV-2 transmission
• Discuss the science regarding SARS-CoV-2 infection control and public health measures
• Recognize the challenges of balancing infection control and public health guidance and buy-in from health care workers and the public
13:10 – 13:40 What’s Hot in Treatment
Speaker: Srinivas Murthy (Vancouver, BC)
By the end of this session, participants should be able to:
• Review the evidence behind COVID-19 treatment options
• Describe the Canadian arm of the WHO’s Solidarity Therapeutics Trial
• Discuss the challenges of navigating treatment guidance in light of politics, press releases, social media, and pre-peer review manuscripts
13:40 – 14:00 Panel Question and Answer
**PROGRAM**

(all times indicated in Canadian Eastern time zone)

**Monday, April 26**

14:00 – 14:15  **Health Break**

14:15 – 15:15  **State of the Art (START) Clinical Lecture**

**What's Hot in COVID-19: Vaccines and Immunity**

Auditorium: Main Auditorium

Moderators: Robert Kozak (Toronto, ON)  
Susan Poutanen (Toronto, ON)

Speaker: Joanne Langley (Halifax, NS)

By the end of this session, participants should be able to:

- Review the effectiveness and adverse events associated with different COVID-19 vaccines
- Describe Canada's approach to COVID-19 vaccine approval, priority group determination, administration, and lessons learned from regional and international approaches
- Describe the impact of variants of concern and expected vaccine effectiveness

16:00 – 18:00  **Live Interaction Poster Presenters at Posters**

Location: Poster Hall

**Tuesday, April 27**

**On Demand Poster Viewing**

**On Demand Exhibit Hall**

**11:30 – 14:00**  **Plenary: Tuberculosis Update**

Auditorium: Main Auditorium

Moderators: Earl Rubin (Montréal, QC)  
Yoko Schreiber (Sioux Lookout, ON)

Speaker: Kathleen McMullin (Prince Albert, SK)

By the end of this session, participants should be able to:

- Increase awareness of the roots of TB inequities for Indigenous Peoples of Canada within a socio-historic and structural perspective
- Promote identification of concrete actions furthering Indigenous self-determination and why it is case-critical for mitigating disproportionate suffering associated with TB
- Spark insight on ways in which integrative knowledge translation between Indigenous wellness systems and conventional TB interventions increase TB program efficacy

12:10 – 12:45  **Advances in TB Diagnostics**

Speaker: Marcel Behr (Montréal, QC)

By the end of this session, participants should be able to:

- Compare the advantages and limitations of nucleic acid amplification to diagnose TB
- Discuss how whole genome sequencing is being applied to the diagnosis of TB
- Appreciate how all new methods require appropriate laboratory controls
### PROGRAM
(all times indicated in Canadian Eastern time zone)

**Tuesday, April 27**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 – 13:25</td>
<td>Treatment of latent TB. Recent advances in new shorter regimens, and new recommendations – by the World Health Organization, and the Centres for Disease Control</td>
<td>Dick Menzies (Montréal, QC)</td>
</tr>
<tr>
<td></td>
<td>By the end of this session, participants should be able to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the advantages of the new shorter Latent TB treat regimens compared to the previously recommended treatment with 9 months Isoniazid (9INH)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weigh the relative benefits and risk of three alternative short latent TB treatment regimens – be better informed about which regimen would be best suited to which types of patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the latest recommendations for treatment of latent TB from two authoritative agencies – the World Health Organization, and the Centres for Disease Control (US)</td>
<td></td>
</tr>
<tr>
<td>13:25 – 14:00</td>
<td>Tuberculosis from birth to adolescence</td>
<td>Ian Kitai (Toronto, ON)</td>
</tr>
<tr>
<td></td>
<td>By the end of this session, participants should be able to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize the common clinical presentation of TB at different ages</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the epidemiology of paediatric TB in Canada and the world including gaps in knowledge</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize the unique vulnerability of young infants to TB disease and the management of the infant born to a mother who has TB disease</td>
<td></td>
</tr>
</tbody>
</table>

### Oral Presentations – Sessions A

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:30</td>
<td>Health Break</td>
<td></td>
</tr>
<tr>
<td>14:30 – 15:45</td>
<td>Oral Presentations – Sessions A</td>
<td>Jennifer Tam (Vancouver, BC)</td>
</tr>
</tbody>
</table>

**AO1**
**Incidence and timing of prosthetic joint infections following primary and revision arthroplasty: a population-based retrospective cohort study**

C Kandel¹, N Daneman², J Widdifield³,⁴,⁵, BE Hansen⁶, R Jenkinson⁷,⁸, A McGeer⁹

¹University of Toronto, Toronto, ON; ²Sunnybrook Health Sciences Centre, Toronto, ON; ³Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto, ON; ⁴Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON; ⁵ICES, Toronto, ON; ⁶Division of Gastroenterology, Toronto General Hospital, University Health Network, Toronto, ON; ⁷Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, ON; ⁸Division of Orthopaedic Surgery, Sunnybrook Health Sciences Centre, Toronto, ON; ⁹Sina Health System, Toronto, ON

**AO2**
**Clinical characteristics, management, and outcomes of patients with indeterminate Clostridioides difficile tests using a modified 2-step algorithm**

LE Burnes¹, SW Smith¹,², K Kowalewska-Grochowska¹,³, JZ Chen¹,²

¹University of Alberta, Edmonton, AB; ²University of Alberta Hospital, Edmonton, AB; ³Provincial Laboratory of Public Health (Microbiology), Edmonton, AB

**AO3**
**Urinary tract infection investigation and treatment in older adults presenting to the emergency department with confusion – A health record review of local practice patterns**

RAM Pinnell¹, T Ramsay², HX Wong³, P Joo²,³

¹Department of Medicine, University of Ottawa, Ottawa, ON; ²Ottawa Hospital Research Institute, Ottawa, ON; ³Department of Family Medicine, University of Ottawa, Ottawa, ON
PROGRAM
(all times indicated in Canadian Eastern time zone)
Tuesday, April 27

A04
Impact of Cobas® PCR Media freezing on SARS-CoV-2 viral RNA integrity and whole genome sequencing analyses
P Benoit1, F Point2, S Gagnon3, D Kaufmann1,2,3, C Tremblay1,2,3, RP Harrigan4, I Hardy1,4,5, F Coutlée1,2,3, S Grandjean-Lapierre1,2,3
1Université de Montréal, Montréal, QC; 2Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC; 3Centre Hospitalier de l'Université de Montréal, Montréal, QC; 4University of British Columbia, Vancouver, BC
14:30 – 15:45 Oral Presentations – Sessions B
Auditorium: Main Auditorium
Moderator: Peter Daley (St. John’s, NL)

B01
Verification of the New bioMérieux Piperacillin/Tazobactam E-Test® against reference broth microdilution
P Lagacé-Wiens1,2, HJ Adam1,2, C Turenne1,2, M Stein1,2, A Walkty1,2, JA Karlowsky1,2
1Shared Health, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB

B02
Performance of matrix-assisted laser desorption/ionization time of flight mass spectrometry for identification of filamentous molds using several different extraction methods
L Li1,2, E Bryce1,2, B Velapatino2, R Najafi1, L Kishi3, B Wang4, C Swanston4, L Hoang2,5, V Tang1, M Charles1,2
1Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; 2Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 3Provincial Health Services Authority, Vancouver, BC; 4Division of Medical Microbiology, Kelowna General Hospital, Kelowna, BC; 5BC Centre for Disease Control, Vancouver, BC

B03
Evaluation of isavuconazole gradient strips for susceptibility testing of Mucorales isolates
L Feng1, L Turnbull2, B Jansen2, TC Dingle1,2
1University of Alberta, Edmonton, AB; 2Alberta Precision Laboratories, Edmonton, AB

B04
Evaluation of whole genome sequencing-based subtyping methods for the surveillance of Shigella flexneri and Shigella sonnei and the confounding effect of mobile genetic elements in propagated outbreaks
I Bernaquez1, C Gaudreau1,2,3, PA Pilon4,5, F Doualla-Bell1, D Roy1, S Bekal1,3
1Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC; 2Microbiologie médicale et infectiologie, Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, QC; 3Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC; 4Direction régionale de santé publique, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal, Montréal, QC; 5Département de médecine sociale et préventive, Université de Montréal, Montréal, QC
17:30 – 19:30 Merit and Association Awards
Masters of Ceremony: Sarah Forgie, AMMI Canada President
Tanis Dingle, CACMID President
Curtis Cooper, CFID President
Auditorium: Unaccredited Presentations
Following the Awards Ceremony, you are invited to join the Awards Chatroom (located inside the Friendly Chat Networking Lounge) to virtually meet and congratulate the recipients and mingle and catch up with fellow attendees.
Tuesday, April 27
17:30 – 19:30

Masters of Ceremony:
Sarah Forgie, AMMI Canada President
Tanis Dingle, CACMID President
Curtis Cooper, CFID President

Auditorium: Unaccredited Presentations

ASSOCIATION OF MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASE CANADA AWARDS

AMMI Canada Distinguished Service Award
2019 – Daniel Gregson

AMMI Canada Lifetime Achievement Award
2019 – Jay Keystone

AMMI Canada Young Investigator Award
2019 – Manish Sadarangani
2020 – Matthew Cheng

AMMI Canada Trainee Research Award
2019 – Samuel Chorlton
2020 – Alice Zhabokritsky

JAMMI Trainee Scientific Article Award
2020 – Brittany Kula

AMMI Canada / bioMérieux Post Residency Fellowship in Microbial Diagnostic
2020 – Jonathon Kotwa

CANADIAN ASSOCIATION OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES AWARDS

John G. FitzGerald – CACMID Outstanding Microbiologist Award
2020 – Michael Mulvey
2021 – Allison McGeer

bioMérieux Award for Leadership in Syndromic Infectious Disease Testing Award
2021 – Marek Smieja

CANADIAN FOUNDATION FOR INFECTIOUS DISEASES AWARDS

Dr. John M. Embil Mentorship Award
2020 – Marcel Behr
2021 – Todd Lee

Dr. Juan A. Embil Award of Excellence in Infectious Diseases Research
2020 – Alexander Lawandi
2021 – Georges Ambaraghassi

CFID Undergraduate Summer Research Grant
2020 - Jonathan Chung and Leslie Fell
2021 - Amaanat Gill and Sayed Zain Ahmad

AMMI Canada Medical Student Research Awards
2020 – Emma Finlayson-Trick and Marissa Nahirney

AMMI Canada – CFID Medical Student Research Award
2021 – Vinyas Harish

altona Diagnostics Canada Medical Student Research Award
2020 - Siena Davis
2021 - Sonia Igboanugo

Following the Awards Ceremony, you are invited to join the Awards Chatroom (located inside the Friendly Chat Networking Lounge) to virtually meet and congratulate the recipients and mingle and catch up with fellow attendees.
On Demand Poster Viewing
On Demand Exhibit Hall

11:00 – 12:00

Auditorium: Co-developed Presentations
Moderators: William Connors (Vancouver, BC) Marthe Charles (Vancouver, BC)
Speakers: Lynora Saxinger (Edmonton, AB) Emily McDonald (Montreal, QC) Zain Chagla (Hamilton, ON)

By the end of the session the participants will be able to:
• Review risk factors for development and progression of COVID-19 and the impact of vaccination
• Implement the use of therapeutics in outpatients with COVID-19, including how to deploy them and to whom
• Discuss the strategic use of therapeutics in inpatients with COVID-19

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Gilead and was planned to achieve scientific integrity, objectivity and balance.

12:00 – 13:00
State of the Art (START) Clinical Lecture

Bacteriophages – Solution to Antimicrobial Resistance?

Auditorium: Main Auditorium
Moderator: William Connors (Vancouver, BC)
Speaker: Steffanie Strathdee (San Diego, CA)

By the end of this session, participants should be able to:
• Understand the biology behind phage therapy
• Appreciate the complexities of phages and phage therapy
• Predict how phage therapy can fail

13:00 – 13:15 Health Break

13:15 – 14:15
State of the Art (START) Clinical Lecture

Use of Artificial Intelligence to Detect and Control Epidemics

Auditorium: Main Auditorium
Moderator: Prameet Sheth (Kingston, ON)
Speaker: Kamran Khan (Toronto, ON)

By the end of this session, participants should be able to:
• Describe a high-level overview of big data and machine learning
• Discuss potential applications of machine learning in microbiology & infectious diseases
• Demonstrate how machine learning and natural language processing have been used to build a global epidemic early warning system

14:15 – 14:30 Health Break

14:30 – 15:45 Oral Presentations – Sessions C

1. C01
Children hospitalized with community-acquired pneumonia complicated by effusion: A single-centre, retrospective cohort study
G Alemayheu, CSJ Lee, JM Pernica
McMaster University, Hamilton, ON

2. C02
Highest prevalence of Mycoplasma genitalium infection among other sexually transmitted diseases and macrolide and fluoroquinolone resistance mediating mutations: A Saskatchewan perspective
NR Parmar1,2, L Mushanski1, T Wanlin2, A Lepe1,2, A Lang1, J Minion3, JR Dillon1,2
1University of Saskatchewan, SK; 2Vaccine and Infectious Disease Organization, SK; 3Saskatchewan Health Authority, Roy Romanow Provincial Laboratory, SK

12:00 – 13:00
State of the Art (START) Clinical Lecture

Bacteriophages – Solution to Antimicrobial Resistance?

Auditorium: Main Auditorium
Moderator: William Connors (Vancouver, BC)
Speaker: Steffanie Strathdee (San Diego, CA)

By the end of this session, participants should be able to:
• Understand the biology behind phage therapy
• Appreciate the complexities of phages and phage therapy
• Predict how phage therapy can fail

13:00 – 13:15 Health Break
PROGRAM
(All times indicated in Canadian Eastern time zone)
Wednesday, April 28

C03
Population level compliance with provincial treatment guidelines for the management of gonorrhea in Alberta, Canada, 2000-2019
A Ugarte Torres1, C Diaz Pallaraz2, J Niruban3, P Smyczek4, D Strong5, J Gratrix5, AE Singh6
1Division of Infectious Diseases, University of Calgary, Calgary, AB; 2Department of Medicine, University of Calgary, Calgary, AB; 3STI Centralized Services, Alberta Health Services, Edmonton, AB; 4Department of Community Health Services, University of Calgary, Calgary, AB; 5Division of Infectious Diseases, University of Alberta, Edmonton, AB

C04
McAlpine1, M Barton2, A Balamohan3, HD Davies2, G Skar4, MA Lefebvre5, D Freire6, NMA Le Saux1, J Bowes1, J Srigley1, P Passarelli1, J Bradley1, S Khan1, R Purewal1, I Viel-Thériault13, A Ranger2, JL Robinson13
1BC Children’s Hospital, Vancouver, BC; 2Victoria Hospital, London, ON; 3Arkansas Children’s Hospital, Little Rock, Arkansas, USA; 4University of Nebraska, Omaha, Nebraska, USA; 5University of Alberta, Alberta, AB; 6University of Ottawa, Ottawa, ON; 7Children’s Hospital of Eastern Ontario, Ottawa, ON; 8Rady Children’s Hospital, San Diego, California, USA; 9McMaster Children’s Hospital, Hamilton, ON; 10Jim Pattison Children’s Hospital, Saskatoon, SK; 11CHU de Québec, Quebec City, QC; 12University of Alberta, Edmonton, AB

14:30 – 15:45 Oral Presentations – Sessions D
Auditorium: Main Auditorium
Moderator: Muhammad Morshed (Vancouver, BC)

D01
Impact of antibiotic prescribing feedback to high volume primary care physicians: A randomized controlled trial
KL Schwartz1,2,3, N Ivers4, BJ Langford1, M Taljaard1, D Neish4, KA Brown1, V Leung5, N Daneman7, J Allo6, M Silverman4, E Shing1, J Grismshaw5, JA Leis7, JHC Wu, G Garber1
1Public Health Ontario, Toronto, ON; 2Dalhousie University, Halifax, NS; 3McMaster University, Hamilton, ON; 4University of British Columbia, Vancouver, BC; 5University of Alberta, Edmonton, AB; 6IWK Health Centre, Halifax, NS; 7University of Ottawa, Ottawa, ON; 8Women’s College Hospital, London, ON; 9Women’s Hospital & Health Centre, Vancouver, BC

D02
Molecular and epidemiological characterization of Adult Healthcare (HA) and Community-Associated (CA) Clostridioides difficile infections 2015-2019, Canada
T Du1, K Baekyung Choi2, R Hizon1, A Silva2, L Pelude1, J Brooks3,4, GN Al-Rawahi5, JC Collett6, B Chow1, JL Comeau1, J Davis2, GA Evans5, C Frenette5, G Han1, SS Hota1, J Johnstone12, KC Katz13, P Kibsey6, J Langley6, BE Lee14, Y Longtin15, D Mertz17, J Minion18, M Science19, J Srigley1, P Stagg20, KN Suh2, N Thampi21, AHM Wong22, on behalf of the Canadian Nosocomial Infection Surveillance Program (CNISP)
1National Microbiology Laboratory, Winnipeg, MB; 2Public Health Agency Canada, Ottawa, ON; 3The Ottawa Hospital, Ottawa, ON; 4BC Children’s Hospital and BC Women’s Hospital & Health Centre, Vancouver, BC; 5Alberta Health Services, Calgary, AB; 6WK Health Centre, Halifax, NS; 7QEI Health Sciences Centre, Halifax, NS; 8Kingston General Hospital, Kingston, ON; 9McGill University Health Centre, Montréal, QC; 10Provinceal Health Services Authority, Vancouver, BC; 11University Health Network, Toronto, ON; 12Sinai Health System, Toronto, ON; 13North York General Hospital, Toronto, ON; 14Royal Jubilee Hospital, Victoria, BC; 15Stollery Children’s Hospital, Edmonton, AB; 16SMBD-Jewish General Hospital, Montréal, QC; 17McMaster University and Hamilton Health Sciences, Hamilton, ON; 18Regina General Hospital, Regina, SK; 19Hospital for Sick Children, Toronto, ON; 20Western Memorial Hospital, Corner Brook, NL; 21Children’s Hospital of Eastern Ontario, Ottawa, ON; 22Royal University Hospital, Saskatoon, SK

D03
Optimizing the treatment of Staphylococcus aureus bloodstream infection with the implementation of a molecular assay and antimicrobial stewardship intervention
Hilal Al Sidairi12, EK Reid1, N Sandila4, J LeBlanc2,3, I Davis2,3, PE Bonnar2,3
1Ibri Referral Hospital, Ministry of Health, Ibri, Oman; 2Dalhousie University, Halifax, NS; 3Nova Scotia Health, Halifax, NS; 4Research Methods Unit, Nova Scotia Health, Halifax, NS

D04
Assessment of empirical vancomycin use and appropriateness at a tertiary care pediatric hospital
K Alsaiger1, J Vayalumkal2, C Constantinescu3
1Pediatric Antimicrobial Stewardship Fellow, University of Calgary, Calgary, AB; 2Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, AB; 3Pediatric Infectious Disease, Clinical Assistant Professor, University of Calgary, Calgary, AB
# PROGRAM

(all times indicated in Canadian Eastern time zone)

**Thursday, April 29**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Auditorium</th>
<th>Moderator</th>
</tr>
</thead>
</table>
| 11:30 - 13:30| **On Demand Poster Viewing**  
**On Demand Exhibit Hall**                                                                 |                           | 11:30 – 13:30     |                                        |
| 11:30 – 12:30| **Plenary: Clinical Controversies**  
**Mandatory Childhood Immunization: Should We Debate This or Consider Our Options?**  
(co-developed by CAIRE: Canadian Association for Immunization, Research, Evaluation and Research) | Main Auditorium           | Titus Wong (Vancouver, BC)  
Manish Sadarangani (Vancouver, BC) |                                        |
| 11:30 – 12:30|                                                                                                 |                           |                  | Moderator:  
Noni MacDonald (Halifax, NS)  
Monika Naus (Vancouver, BC) |                                        |
| 12:30 – 13:30| **To Screen or Not to Screen: VRE-Evaluating the Data**  
**Debaters:**  
- For hospital IPAC programs screening for VRE  
  - Stephanie Smith (Edmonton, AB)  
- Against hospital IPAC programs screening for VRE  
  - A Jassem1, MG Morshed3, A Olmstead4, V Barakauskas2, J Simons3, S Masood4, M Charles5, A Hayden6, M Krajden1 | Exhibit Hall                | Vanessa Tran (Toronto, ON) |                                        |

### E01

**Waning anti-nucleocapsid IgG signal among SARS-CoV-2 seropositive blood donors: May- November 2020**

S Saeed1, SJ Drews2, C Pambrun3, SF O’Brien1

1Canadian Blood Services, Epidemiology and Surveillance, Ottawa, ON; 2Canadian Blood Services, Microbiology, Edmonton, AB; 3University of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, AB; 4Canadian Blood Services, Medical Affairs and Innovation, Ottawa, ON

### E02

**SARS-CoV-2 Serology: Validation of high-throughput Chemoluminescent Immunassay (CLIA) platforms and a field study in British Columbia**

AS Mak1, I Sekirov1, D Cook1, P Levett1, A Jassem1, MG Morshed3, A Olmstead4, V Barakauskas2, J Simons3, S Masood4, M Charles5, A Hayden6, M Krajden1

1BC Center for Disease Control, Vancouver, BC  
2Children’s and Women's Hospital, Vancouver, BC; 3St. Paul's Hospital, Providence Health, Vancouver, BC; 4Surrey Memorial Hospital, Surrey, BC; 5Vancouver General Hospital, Vancouver, BC; 6Vancouver Coastal Health Authority, Vancouver, BC

---

**By the end of this session, participants should be able to:**

- Review the concepts related to mandatory childhood immunization
- Describe the impact of COVID-19 on uptake of childhood immunization and its potential implications and solutions, including the role of 'mandatory' models

**By the end of this session, participants should be able to:**

- Define the clinical impact of VRE infection and understand the changing clinical epidemiology of VRE in Canadian hospitals
- Discuss the evidence for and against VRE control programs
- Recognize the gaps in knowledge around VRE prevention and control
PROGRAM
(all times indicated in Canadian Eastern time zone)
Thursday, April 29

**E03**

**Analysis of the performance of water gargle samples for SARS-CoV-2 detection using heat extraction followed by laboratory-developed nucleic acid amplification testing**

S Gobeille Paré¹, J Bestman-Smith¹, J Fafard², F Doualla-Bell², M Jacob-Wagner¹, M St-Hilaire¹, S Beauchemin¹, V Boucher³, F Vancol-Fable¹, C Lavallée⁴, AC Labbé⁵,⁶

¹Centre Hospitalier Universitaire de Québec - Université Laval, Québec, QC; ²Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC ³CIUSSS de l’Est-de-l’Île-de-Montréal, Montréal, QC; ⁴Centre Hospitalier Universitaire de Montréal, Montréal, QC ⁵Université de Montréal, Montréal, QC

By the end of this session, participants should be able to:

- Discuss the drivers of emerging zoonotic infections, how they are being affected in the Anthropocene and their implications for future research and knowledge mobilization.
- Propose a 5-step pathway to rising to the challenges of emerging zoonoses in these times of unprecedented change and accelerating exceptions to prevent the next pandemic

Friday, April 30

**10:00 - 12:00**

**Live Interaction**

**Poster Presenters at Posters**

Location: Poster Hall

**10:00 - 12:00**

**Live Interaction**

**Exhibitors at Exhibit Booths**

Location: Exhibit Hall

**12:30 – 13:30**

**State of the Art (START) Clinical Lecture**

**Zoonoses and Preparedness in the Anthropocene**

Auditorium: Main Auditorium
Moderator: Robert Kozak (Toronto, ON)
Speaker: Craig Stephen (Nanoose Bay, BC)

By the end of this session, participants should be able to:

- Discuss the drivers of emerging zoonotic infections, how they are being affected in the Anthropocene and their implications for future research and knowledge mobilization.
- Propose a 5-step pathway to rising to the challenges of emerging zoonoses in these times of unprecedented change and accelerating exceptions to prevent the next pandemic

**13:30 – 13:45**

**Health Break**
**PROGRAM**

(all times indicated in Canadian Eastern time zone)

**Friday, April 30**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Auditorium</th>
<th>Moderator(s)</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45 - 15:45</td>
<td>Plenary: What's Hot in Adult and Paediatric Infectious Diseases, Infection Control and Diagnostic Microbiology? (co-developed by CFID: Canadian Foundation for Infectious Diseases)</td>
<td>Main Auditorium</td>
<td>Shariq Haider (Hamilton, ON) David Patrick (Vancouver, BC)</td>
<td>Natasha Press (Vancouver, BC)</td>
</tr>
<tr>
<td>13:45 - 14:15</td>
<td>What's Hot in Adult Infectious Disease</td>
<td>Main Auditorum</td>
<td>Shariq Haider (Hamilton, ON) David Patrick (Vancouver, BC)</td>
<td>Natasha Press (Vancouver, BC)</td>
</tr>
<tr>
<td>14:45 - 15:15</td>
<td>What's Hot in Paediatric Infectious Disease</td>
<td>Main Auditorum</td>
<td>Joan Robinson (Edmonton, AB)</td>
<td>David Goldfarb (Vancouver, BC)</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>Closing Remarks and Student Awards Presentations</td>
<td>Main Auditorum</td>
<td>Tanis Dingle (Edmonton, AB) Sarah Forgie (Edmonton, AB)</td>
<td>Tanis Dingle (Edmonton, AB) Sarah Forgie (Edmonton, AB)</td>
</tr>
</tbody>
</table>

By the end of this session, participants should be able to:
- Describe recent new findings that impact the practice of adult infectious diseases
- Describe recent new findings that impact the practice of paediatric infectious diseases
- Describe recent new findings that impact the practice of diagnostics microbiology
- Describe recent new findings that impact the practice of infection prevention and control

**POSTER AND ORAL AWARDS**

- Association of Medical Microbiology and Infectious Disease (AMMI) Canada Poster Award
- Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Technologist Poster Award
- Canadian College of Microbiologists (CCM) Poster Award
- Dr. Kenneth Rozee Memorial Poster Award
- Dr. Susan King Paediatric Abstract Award

- Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Student Oral Presentation Award
- Canadian College of Microbiologists (CCM) Dr. Kenneth Rozee Memorial Poster Award
- Canadian College of Microbiologists (CCM) Dr. Susan King Paediatric Abstract Award
Vancouver
April 6 – 9, 2022

Save the date!
MARCEL BEHR
Marcel Behr is a clinician-scientist with appointments of Full Professor in the Department of Medicine and Associate member in the departments of Epidemiology and Biostatistics as well as Microbiology and Immunology. He was the founding Director of the McGill International TB Centre and led it from 2012 to 2018. He is the Associate Program Leader of the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Centre since 2016 and in 2017 he became the co-Director the McGill Interdisciplinary Initiative in Infection and Immunity (McGill-i4). He is the interim director of McGill Infectious Diseases Division. Dr. Behr trained at the University of Toronto, Queen’s, McGill and Stanford. His work has been recognized by election into the Canadian Academy of Health Sciences, the Royal Society of Canada, the American Society for Clinical Investigation and the American Academy of Microbiology. Dr. Behr’s lab uses bacterial genomic methodologies to study the epidemiology and pathogenesis of tuberculosis and other mycobacterial diseases.

ZAIN CHAGLA
Zain Chagla is an M.D. specializing in internal medicine, tropical medicine, and infectious diseases, he is Medical Director, Infection Control, at St. Joseph’s Hospital and Hamilton Health Sciences, Niagara Health, and is a consultant at Woodstock General Hospital. He is an associate Professor of Medicine at McMaster University, and adjunct faculty at the University of Namibia in the Department of Medicine. He also received his M.Sc from the London School of Hygiene and Tropical Medicine, and a Diploma in Tropical Medicine completed in Tanzania and Uganda through the London School of Hygiene and Tropical Medicine. Dr. Chagla has been a part of COVID-19 clinical trials, infection control and testing, and epidemiology.

DAVID GOLDFARB
David Goldfarb MD FRCPC is a Clinical Associate Professor in the Department of Pathology and Laboratory Medicine at University of British Columbia and Medical Microbiologist and Pediatric Infectious Disease Physician at BC Children’s Hospital. His research focuses on novel diagnostic, prevention, and management strategies for childhood infectious diseases particularly in remote and resource limited settings. He leads several research projects in sites in Africa and northern Canada.

JENNIE JOHNSTONE
Jennie Johnstone obtained her medical degree from Dalhousie University. She then moved to Edmonton, Alberta where she completed her Internal Medicine and Infectious Disease training at the University of Alberta. Following her residency, she completed a clinical research fellowship in Edmonton. She moved to Hamilton in July 2008 where she practiced Infectious Diseases at McMaster University and completed her PhD in Health Research Methodology (Epidemiology). Following her PhD, she joined Public Health Ontario as an Infection Prevention and Control physician where she continues to lead research focused on Infection Prevention and Control in the areas of vancomycin resistant enterococci, ventilator associated pneumonia and Clostridium difficile. She worked at St. Joseph’s Health Center in Toronto for 5 years, where she practiced Infectious Diseases and ran the Infection Prevention and Control program. In 2018 she left St. Joseph’s to become a physician co-lead of Infection Prevention and Control at Sinai Health System in Toronto where she is also an Assistant Professor in the Laboratory Medicine and Pathobiology and Dalla Lana School of Public Health, University of Toronto.
KAMRAN KHAN
Kamran Khan is an infectious disease physician-scientist and a Professor of Medicine and Public Health at the University of Toronto. Motivated by his experiences as a frontline healthcare worker during the 2003 Toronto SARS outbreak, Dr. Khan has been studying outbreaks of emerging and re-emerging diseases for more than a decade to lay the scientific foundation for a global early warning system for infectious diseases. To translate and disseminate scientific knowledge into timely action, Dr. Khan founded BlueDot in 2013, a digital health company that combines human and artificial intelligence to help governments protect their citizens, hospitals protect their staff and patients, and businesses protect their employees and customers from dangerous infectious diseases. Dr. Khan recently received a Governor General's Award for his work transcending clinical medicine, public health, big data, and artificial intelligence.

IAN KITAI
Ian Kitai is Tuberculosis Specialist at SickKids and first author of the paediatric chapter of the Canadian TB standards, as well as many publications related to childhood TB. He has worked in rural Zimbabwe with Oxfam UK and in Norway House, Manitoba with the Northern Medical Unit of University of Manitoba. He is a professor in the Department of Paediatrics at the University of Toronto.

ROBERT KOZAK
Robert Kozak completed his PhD in microbiology and immunology at McGill University. Following this he completed post-doctoral fellowships in viral hepatitis and zoonotic viruses at McGill and the Ontario Veterinary College, University of Guelph, respectively. Before entering the clinical microbiology training program at the University of Toronto, he trained at the Special Pathogens Program at the National Microbiology Laboratory in Winnipeg where he studied viral hemorrhagic fevers, and zoonotic viruses. During this time, he led teams investigating Ebola virus transmission in animals models and developing vaccines and countermeasures for Crimean Congo Hemorrhagic fever virus. Additionally, he was involved in projects investigating Middle East Respiratory Syndrome coronavirus, hantavirus and Zika virus. He also serves on the boards of the Canadian College of Microbiologists and the Canadian Association of Clinical Microbiology and Infectious Diseases. Currently he works as a clinical microbiologist at Shared Hospital Laboratory at Sunnybrook Health Sciences Centre. Recently his research has focused on COVID-19 specifically in the areas of diagnostics, and the development and evaluation of vaccines and therapeutics.

MEL KRAJDEN
Mel Krajden MD, FRCP is the Medical Director of the BC Centre for Disease Control Public Health Laboratory and the Medical Head of Hepatitis at the British Columbia Centre for Disease Control. He is also a Professor of Pathology and Laboratory Medicine at the University of British Columbia. He currently a member of Federal COVID Immunity Task Force and facilitates the Testing Working Party. His laboratory research involves the application of molecular techniques to diagnose viruses, assess correlates between infection and clinical disease, and track microbial infections for epidemiological purposes. His clinical research involves integration of hepatitis prevention and care services which involves the use of linked laboratory and administrative data to help understand how to measure population level health outcomes for policy making. He has extensive clinical trials expertise and has received CIHR funding in the fields of human papillomavirus, HIV, hepatitis C virus and COVID-19. He is also a Co-PI/Mentor for CIHR funded Canadian Hepatitis C Network (CanHepC) and has >300 publications.

JOANNE LANGLEY
Joanne Langley is a Professor of Pediatrics and Community Health and Epidemiology at Dalhousie University and the Canadian Center for Vaccinology in Halifax, NS Canada, head of Pediatric Infectious Diseases at the IWK Health Centre, and lead for the Clinical Trials Network of the Canadian Immunization Research Network. She currently co-chairs the Canadian COVID-19 Vaccine Task Force. Her research is focused on the epidemiology and vaccine prevention of respiratory infections, particularly Respiratory Syncytial Virus and influenza, and immunization decision making.
NONI MACDONALD
Noni MacDonald is a Professor of Paediatrics (Infectious Diseases) at Dalhousie University and the IWK Health Centre in Halifax Canada and a former Dean of Medicine at Dalhousie University. Her two current major areas of interest involve global health. The first is vaccines, including vaccine safety, hesitancy, demand, pain mitigation, education and policy especially through her work with the World Health Organization (WHO). She has been a member of SAGE (the Strategic Advisory Group of Experts on immunization for WHO) since 2017. The second area of interest is MicroResearch (www.microresearchinternational.ca), building capacity in community focused research in developing countries. She has published over 450 papers; was the founding Editor-in-Chief of Paediatrics & Child Health for over 20 years, and a former Editor-in-Chief of CMAJ (Canadian Medical Association Journal). Dr. MacDonald has long been recognized in Canada and internationally, as an advocate for children and youth health and as a leader in paediatric infectious disease and global health. She is an Officer of the Order of Canada and a recipient of the Order of Nova Scotia.

EMILY MCDONALD
Emily McDonald is an Associate Professor of Medicine in General Internal Medicine at McGill University, Scientist at the Research Institute of the McGill University Health Centre and Director of a research unit for the Department of Medicine- the Clinical Practice Assessment Unit. She completed medical school, residency and a Masters in Epidemiology at McGill University, and post-graduate research training in Toronto and at the Harvard School of Public Health. She was recently named to the Canadian Task Force for Preventive Health Care and is the Associate Chair of Quality and Safety for the McGill University Department of Medicine. Dr. McDonald has helped lead several international clinical trials of repurposed medications for the treatment of COVID-19 since the pandemic began in March 2020.

KATHLEEN MCMULLIN
Kathleen McMullin is a member of the Lac La Ronge Indian Band in northern Saskatchewan and she resides in Prince Albert, Saskatchewan. Kathleen holds a Bachelor of Education degree and a Master’s degree in Indigenous and Northern Education. Currently, she is a PhD Candidate at the Department of Health Sciences, College of Medicine, University of Saskatchewan and her thesis topic is ‘Standing in the Matriarchal Footsteps of our Cree Grandmothers’ which is about the impact of colonization on traditional home stewardship and is a strength-based approach to revitalizing and reinforcing the culture, pride, skills and values in contemporary Indigenous homes and housing. Kathleen works part time as a Cultural Engagement Advisor for Queen’s University on a CIHR funded project entitled ‘Recurrent tuberculosis in Canada - translating whole genome sequence insights into best public health practice’. Prior to this study, Kathleen also worked with the Determinants of TB Project from 2006 - 2012 as a research coordinator for the University of Saskatchewan and the Tuberculosis Population Evaluation Research Unit (TBPERU), University of Alberta. Following this position, from 2011 to 2012 she was Research Manager for the TBPERU’s ‘Tuberculosis Education in Aboriginal and non-Aboriginal Youth: An Historical, Socio-cultural and Public Health Promotional Curriculum Project’. Then, from 2012 to 2013, Kathleen became Research Manager for the project ‘Assess, Redress, Re-assess: Addressing Disparities in Respiratory Health among First Nations People’ at the Canadian Centre for Health and Safety in Agriculture Research (CCHSAR), University of Saskatchewan.

DICK MENZIES
Dick Menzies received his medical training at McGill University, Montreal and specialty training in Internal Medicine at the Medical College of Pennsylvania in Philadelphia, USA. He then worked for 2 ½ years in Lesotho, Africa, where he was first exposed (literally) to tuberculosis – in all its forms, and with all its devastation. He then received sub-specialty training in Respiratory Medicine and a Master’s degree in Epidemiology & Biostatistics at McGill University. Dr. Menzies served as Medical Director at the Montreal Chest Institute for a total of 10 years ending in 2002, and then as Director of the Respiratory Division for 9 years. He is now Director of the McGill International TB Centre, and the McGill WHO Collaborating Centre in TB Research.
DOMINIK MERTZ
Dominik Mertz attended medical school and completed his training in Internal Medicine and Infectious Diseases in Switzerland prior to moving to Canada to complete a Master’s Degree in Health Research Methodology/ Clinical Epidemiology at McMaster University, Hamilton, ON. He is currently an Associate Professor in the Department of Medicine and is affiliated with the Departments for Health Research Methods, Evidence and Impact, the Department of Pathology and Molecular Medicine, the Population Health Research Institute (PHRI), and the Michael G. DeGroote Institute for Infectious Diseases Research at McMaster University. He is a practising infectious diseases physician and is serving as the Medical Director Infection Prevention and Control at Hamilton Health Sciences. His particular research interest is the epidemiology and prevention of hospital-acquired infections including surgical site infections, antimicrobial stewardship, and quality improvement. He published >100 peer reviewed articles to date. He is an associate editor for BMC Infectious Diseases and served as the first-named editor for the 3rd edition of the book ‘Evidence-based Infectious Diseases’. He is involved in the Canadian Nosocomial Infection Surveillance Program (CNISP), the Society of Healthcare Epidemiology of America (SHEA), and the AMMI Research Network steering committee and of the Ontario Provincial Infectious Diseases Advisory Committee (PIDAC). He is also serving on multiple provincial, regional and local taskforces and committees in relation to the COVID-19 pandemic.

MATTHEW MILLER
Dr. Miller is an Associate Professor, Associate Chair, and Assistant Dean in the Department of Biochemistry and Biomedical Sciences at McMaster University. He is also a member of the Michael G. DeGroote Institute for Infectious Diseases Research and the McMaster Immunology Research Centre. Dr. Miller also serves as a member of the and as Secretary-Treasurer of the Canadian Society for Virology. Dr. Miller completed his PhD in Microbiology & Immunology at the University of Western Ontario, where he studied the molecular virology and pathogenesis of DNA viruses. He went on to complete a CIHR-funded postdoctoral fellowship with Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai in New York, NY where his research focus shifted to the design of “universal” influenza virus vaccines. Dr. Miller was recruited to McMaster University in 2014 as an Assistant Professor where his research has been focused on issues related to influenza virus pandemic preparedness – especially vaccinology. He has been awarded a CIHR New Investigator Award, the CIHR Bhagirath Singh Early Career Award in Infection and Immunity, an and Early Researcher Award from the Government of Ontario. Since early 2020, Dr. Miller has been heavily engaged in COVID-19 research, including development of next-generation COVID-19 vaccines, therapeutics, and diagnostics. He serves as the SARS-CoV-2 CL3 supervisor for McMaster University and is a member of the National Advisory Committee on Immunization (NACI) High Consequence Infectious Disease Working Group, which makes recommendations to inform the use of COVID-19 vaccines in Canada.

SRINIVAS MURTHY
Srinivas Murthy is the Innovative Medicines Canada and Health Research Foundation Chair in Pandemic Preparedness Research. He is Clinical Associate Professor at the University of British Columbia in Vancouver, Canada. His research focuses on the treatment of severe infections, global outbreak response, and innovative clinical trials.

MONIKA NAUS
Monika Naus is the Medical Director of the Communicable Diseases & Immunization Service, Head of Vaccine Preventable Diseases & Immunization Programs at the British Columbia Centre for Disease Control, and Professor at the School of Population and Public Health at the University of British Columbia. Dr. Naus obtained her medical training at the University of Alberta and her training in Public Health and Preventive Medicine at the University of Toronto. She then served as a federal field epidemiologist with the Laboratory Centre for Disease Control prior to starting her career in public health, with a focus on communicable disease prevention and control. Before joining BCCDC in July 2001, she was the provincial epidemiologist in Ontario from 1997 to 2001, and a senior medical
LYNORA SAXINGER
Lynora Saxinger, CTrOpMed, MD, FRCPC, is an University of Alberta based Infectious Diseases specialist whose clinical practice includes HIV, Hepatitis C, nontransplant immunocompromised hosts, and Travel and Tropical Medicine. Her pre pandemic role is Co-Chair of the Alberta Health Services Antimicrobial Stewardship Committee, and she is involved in national Stewardship initiatives to promote best practices in antibiotic use, evaluation of surveillance of Antimicrobial Utilization and Antimicrobial Resistance through a One-Health lens, and derivation of Stewardship best practices. Her pandemic role is co-lead of the Alberta COVID-19 Scientific Advisory Group, and engagement in social media and media based scientific communication and knowledge translation for public education around COVID-19.

YOKO SCHREIBER
Yoko Schreiber completed her training and worked several years at The Ottawa Hospital / University of Ottawa, Yoko decided to move closer to communities she wished to serve and relocated to Sioux Lookout, Ontario. Yoko currently holds a position as an Assistant Professor both at NOSM and University of Manitoba, and spends her time providing general ID clinical care Sioux Lookout region, which covers over 28 remote First Nations communities, as well as spending several weeks a year in Winnipeg. Her practice spans from clinical care to assisting the local health authority with public health issues and includes research, education and involvement in national committee work (FNIHB, AMMI). In all, she considers herself the luckiest ID physician in the country, being able to practice ID in a setting where it is needed most, surrounded by lakes and outdoor opportunities in Ontario’s “sunset country.”

STEPHANIE SMITH
Stephanie Smith is a professor in the Division of Infectious Diseases at the University of Alberta. She is trained in adult infectious diseases and her clinical practice includes care of inpatients with complicated infections, outpatient HIV and viral hepatitis. She is Director of Infection Prevention and Control at the University Hospital and Mazankowski Heart Institute. She is involved in local, provincial and
national committees related to infection prevention and control, hospital acquired infection surveillance and prevention of antimicrobial resistance. She is involved in education of infectious diseases trainees at both the local and national level.

CRAIG STEPHEN
Craig Stephen DVM PhD, is a clinical professor at both the School of Population and Public Health (UBC) and the Ross School of Veterinary Medicine. He is an ecohealth and One Health practitioner who has worked at the interface of human, animal and environmental health for 25 years. He has worked extensively on emerging infectious diseases in Canada and in a global health context. Craig's current focus is on adapting harm reduction and health promotion concepts to develop a reciprocal care approach to health threats of the Anthropocene shared by people, animals and ecosystems. This includes promoting nature-based approaches to pandemic prevention and recovery. He has over 200 peer-reviewed and technical publications and has edited 4 books on these subjects, most recently, Animals Health and Society: Health Promotion, Harm Reduction and Health Equity in a One Health World.

STEFFANIE STRATHDEE
Steffanie Strathdee is a Canadian-American infectious disease epidemiologist trained at the University of Toronto. She is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego where she codirects the Center for Innovative Phage Applications and Therapeutics (IPATH), and Adjunct Professor at Johns Hopkins and Simon Fraser Universities. In 2016, Strathdee and colleagues were credited with saving her husband's life from a deadly superbug infection using bacteriophages – viruses that attack bacteria. The case, which involved cooperation from three universities, the U.S. Navy and researchers across the globe, shows how phage therapy is a future weapon against multi-drug resistant bacterial infections which are expected to kill 10 million people per year by 2050. Strathdee co-authored a book on their story called The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug. For her efforts to revitalize phage therapy in the West, she was named one of TIME magazine's Most Influential People in Health Care in 2018.

THERESA TAM
Theresa Tam was named Canada's Chief Public Health Officer (CPHO) on June 26, 2017. She is a physician with expertise in immunization, infectious disease, emergency preparedness and global health security. As the federal government’s lead health professional, Dr. Tam provides advice to the Minister of Health, supports and provides advice to the President of the Public Health Agency of Canada, and works in collaboration with the President in the leadership and management of the Agency. The Public Health Agency of Canada Act empowers the CPHO to communicate with other levels of government, voluntary organizations, the private sector and Canadians on public health issues. Each year, the CPHO is required to submit a report to the Minister of Health on the state of public health in Canada.

TITUS WONG
Titus Wong completed his MD and Medical Microbiology residency at the University of British Columbia and earned a Master’s in Health Science (Clinical Epidemiology) from the UBC School of Population and Public Health. Titus joined the Division of Medical Microbiology and Infection Prevention at Vancouver Coastal Health (VCH) in 2012 and currently serves as the Regional Medical Director for Infection Prevention and Control at VCH and as the co-Medical Director of the BC Provincial Infection Control Network with the Provincial Health Services Network. Titus has research interests in the testing and clinical application of environmental infection control strategies and has been working tirelessly with the IPAC team to support the pandemic response in British Columbia.
**E-POSTERS**

On Demand starting Sunday, April 25

**Poster Hall**

---

**Live Interaction,**

**Poster Presenters at Posters**

*participation by presenters may vary*

**Monday, April 26**  
16:00 – 18:00 EDT

**Wednesday, April 28**  
15:45 – 17:45 EDT

**Thursday, April 29**  
16:15 – 18:00 EDT

**Friday April 30**  
10:00 – 12:00 EDT

---

**P01**

**OPAT quality indicators at a tertiary care centre reveal vast room for improvement**

JL Martinez-Cajas¹, S McKenna², B Alvarado-Llano¹, E Wilson¹, K Leifso³, S Perez-Patrigeon¹, GA Evans¹

¹Queen’s University, Kingston, ON; ²Kingston Health Sciences Centre, Kingston, ON

---

**P02**

**Outcomes of a risk-based decision-making process for reducing the risk of Hepatitis E virus transfusion transmission via the Canadian blood supply**

S Ward¹, G Delage², Y Gregoire³, G Hawes³, C Brennan¹, L Potter¹, M Fearon⁶, C Simpson⁶,²,⁷, M McDonald²,⁷, B Knoppers⁷,¹⁰, S O’Brien¹, SJ Drews¹¹,¹²

¹Canadian Blood Services, Ottawa, ON; ²Héma-Québec, Québec, QC; ³Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON; ⁴Canadian Blood Services, Ottawa, ON; ⁵Medical Affairs and Innovation, Héma-Québec, Saint-Laurent, QC; ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre, Montréal, QC; ⁷Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC; ⁸Canadian Blood Services, Edmonton, AB; ⁹Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; ¹⁰Population Health and Optimal Health Practices Research Unit, Trauma-Emergency-Critical Care Medicine, CHU de Québec, Université Laval Research Center, Québec, QC; ¹¹Pediatrics Department, Intensive Care Division, Faculté de Médecine, Université Laval, Québec, QC; ¹²Transplant Québec, Montréal, QC; ¹³Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC

---

**P03**

**Evaluation of the NG-Test Carba 5 Multiplex Immunochromatographic Assay and Cepheid Xpert Carba-R Assay for the detection of Carbapenemase genes in gram negative organisms**

GN Al-Rawahi¹²,* R Penny¹, A Cuarte¹, S Dhaliwal¹, T Chen¹, D Purych²,³, D Boyd⁴, L Hoang⁵, P Tilley¹²

¹BC Children’s Hospital, Vancouver, BC; ²University of British Columbia, Vancouver, BC; ³Fraser Health, Surrey, BC; ⁴Public Health Agency of Canada, Winnipeg, MB; ⁵Public Health Microbiology and Reference Laboratory, Vancouver, BC

---

**P04**

**SARS-CoV-2 transmission through cells, tissues and organs transplantation**

A Gaussen¹, L Hornby²,³, G Rock¹, S O’Brien¹, G Delage¹, R Sapir-Pichhadze⁶,⁷, SJ Drews⁸,⁹, MJ Weiss¹⁰,¹¹,¹², A Lewin¹³

¹Medical Affairs and Innovation, Héma-Québec, Québec, QC; ²Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON; ³Canadian Blood Services, Ottawa, ON; ⁴Medical Affairs and Innovation, Héma-Québec, Saint-Laurent, QC; ⁵Centre for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre, Montréal, QC; ⁶Division of Nephrology and the Multi Organ Transplant Program, Royal Victoria Hospital, McGill University Health Centre, Montréal, QC; ⁷Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC; ⁸Canadian Blood Services, Edmonton, AB; ⁹Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; ¹⁰Population Health and Optimal Health Practices Research Unit, Trauma-Emergency-Critical Care Medicine, CHU de Québec, Université Laval Research Center, Québec, QC; ¹¹Pediatrics Department, Intensive Care Division, Faculté de Médecine, Université Laval, Québec, QC; ¹²Transplant Québec, Montréal, QC; ¹³Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC
**P05**
One Health genomic study of extended spectrum beta-lactamases (ESBL)-producing Salmonella enterica in Canada, 2012-2016
A Bharat1,2, L Mataseje1, Rj Parmley3,4, BP Avery3, G Cox1,2, C Carson4, RJ Irwin3, AE Deckert4, D Daignault5, DC Alexander6, VG Allen7, S El Bailey8, S Bekal9, L Chui10, GJ German11, D Haldane12, L Hoang13, J Minion14, G Zahariadis15, RJ Reid-Smith16, MR Mulvey1
1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 2Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB; 3Department of Population Medicine, University of Guelph, Guelph, ON; 4Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada, Guelph, ON; 5National Microbiology Laboratory, Public Health Agency of Canada, St. Hyacinthe, QC; 6Cadham Provincial Laboratory, Winnipeg, MB; 7Public Health Ontario Laboratories, Toronto, ON; 8Horizon Health Network, Saint John, NB; 9Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC; 10Alberta Precision Laboratories-Provincial Laboratory for Public Health, Edmonton, AB; 11Queen Elizabeth Hospital, Charlottetown, PE; 12Queen Elizabeth II Health Sciences Centre, Halifax, NS; 13British Columbia Centres for Disease Control, Vancouver, BC; 14Roy Romanow Provincial Laboratory, Regina, SK; 15Newfoundland and Labrador Public Health and Microbiology Laboratory, St. John’s, NL

**P07**
A virtual care model utilizing patient directed oximetry monitoring for outpatients with COVID-19: A quality improvement study
MK Devlin1,2, MJ Nicholson1,2, JA Ernst1,3, I Dhaliwal1,3, M Mrkobrada1,3, E Spicer1,3
1Western University, London, ON; 2St. Joseph’s Health Centre, London, ON; 3London Health Sciences Centre, London, ON

**P08**
Case report: Actinotignum schaalii identified in a neck abscess of a pediatric patient
RM Kariyawasam1,2, EM Morin3, E Eksteen4, K Kowalewska-Grochowska1,2,5
1Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB; 2Alberta Precision Labs-Public Health, Edmonton, AB; 3Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alberta, Edmonton, AB; 4Division of Otolaryngology, Department of Surgery, University of Alberta, Edmonton, AB; 5Division of Medical Microbiology & Immunology, Department of Medicine, University of Alberta, Edmonton, AB

**P09**
Synergistic activity of combinations of colistin with other antibiotics against multidrug- and extensively drug resistant clinical isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa
TA Petrovskaya, DV Tapalski
Gomel State Medical University, Gomel, Belarus

**P10**
The vancomycin minimum inhibitory concentration of Staphylococcus species isolated from children’s blood culture
EYH Yeung1,2, NMA Le Saux3
1University of Ottawa, Ottawa, ON; 2Eastern Ontario Regional Laboratory Association, Ottawa, ON; 3Children’s Hospital of Eastern Ontario, Ottawa, ON

**P11**
Microbiological efficiency of the combinations of two carbapenems against Klebsiella pneumoniae carbapenemase-producing strains
EV Timoskova, DV Tapalski
Gomel State Medical University, Gomel, Belarus
Waning anti-SARS-CoV-2 plaque reduction neutralization test titers in repeat Canadian convalescent plasma donors: April-December 2020

Sj Drews1,2, DV Devine3,4, J McManus4, E Mendoza5, K Manguiat5, R Girardin6, A Dupuis6, K McDonough6,7, YCJ Lin6,8, DH Evans6,9, C Pambrun10, M Drebot5,11, H Wood5

1Canadian Blood Services, Microbiology, Edmonton, AB; 2Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; 3Canadian Blood Services, Vancouver, BC; 4Centre for Blood Research and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 5Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 6Wadsworth Center, New York State Department of Health, Albany, NY, USA; 7Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY, USA; 8Medical Microbiology & Immunology, University of Alberta, Edmonton, AB; 9Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB; 10Canadian Blood Services, Medical Affairs and Innovation, Ottawa, ON; 11Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB

Impact of the COVID-19 pandemic on the incidence and serotype distribution of invasive pneumococcal disease in south-central Ontario

A McGeer1, KR Barker2, A Campigotto3, L Matukas4, D Richardson4, C Vermeiren6, R Lovinsky7, N Farshakit8, A Plevenshii9, K Hassan1, I Martin9

1Sinai Health System, Toronto, ON; 2Trillium Health Partners, Mississauga, ON; 3Hospital for Sick Children, Toronto, ON; 4Unity Health, Toronto, ON; 5William Osler Health System, Brampton, ON; 6Shared Health Laboratories, North York, ON; 7Scarborough Health Network, Toronto, ON; 8Humber River Hospital, Toronto, ON; 9National Microbiology Laboratory, Winnipeg, MB

Penicillin susceptibility in *Staphylococcus aureus* – An opportunity for antimicrobial stewardship?

P Lagacé-Wiens1,2, M Stein1,2, P Pieroni1, HJ Adam1,2, CY Turenne1,2, A Walkty1,2, T Wuerz1,3, JA Karlowsky1,2

1Shared Health, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB; 3Saint-Boniface Hospital, Winnipeg, MB

Nosocomial SARS-CoV-2 infection in healthcare workers (HCWs): descriptive analysis of a large acute care hospital COVID-19 outbreak on cardiac units

D Dixit1,2, JM Conly1,3, K Snedeker1,3, N Etches1,3, A Weiss1, M Suddes1, P Jameison3,1,3, S Tsekrekos1,4

1Alberta Health Services, Calgary, AB; 2University of Saskatchewan, Saskatoon, SK; 3University of Calgary, Calgary, AB; 4University of Alberta, Edmonton, AB

Impact of an antimicrobial stewardship initiative to reduce asymptomatic bacteriuria in a tertiary hospital

MO Wong, N Makhoulain, S Hosseini, K Afra

Fraser Health, Surrey, BC

Evaluation of the Solana® Influenza A and B nucleic acid amplification assay

P Lagacé-Wiens1,2, M Stein1,2, P Pieroni1, HJ Adam1,2, CY Turenne1,2, A Walkty1,2, JA Karlowsky1,2

1Shared Health, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB

Stepwise implementation of an antimicrobial stewardship prospective audit and feedback intervention at a large academic centre in Canada

JZ Chen1,2, C Cervera1, SW Smith1,2, D Kabbani1,2, C Lau1, S Bains3, K Fong1, J Stewart4, KE Doucette1,2

1Division of Infectious Diseases, University of Alberta, Edmonton, AB; 2Alberta Health Services, Edmonton, AB; 3Pharmacy Services, Alberta Health Services, Edmonton, AB
P21
SARS-CoV2 outbreak amongst physicians at a Canadian curling bonspiel: a descriptive observational study
B Meatherall1, S Law2, C Rice3, J Hu3, C Fung4, A Woo5, K Fonseca5, A Lang6, J Kanji3, K Burak5,1
1Division of Infectious Diseases, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB; 2Physician Learning Program, Continuing Medical Education and Professional Development, Cumming School of Medicine, University of Calgary, Calgary, AB; 3Medical Officer of Health, Alberta Health Services; Department of Community Health Sciences, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB; 4Department of Radiology and Diagnostic Imaging, Faculty of Medicine and Dental Surgery, University of Alberta, Edmonton, AB; 5Division of Orthopedics, Department of Surgery, College of Medicine, University of Saskatchewan, Saskatoon, SK; 6Provincial Laboratory for Public Health, Alberta Precision Laboratories, Calgary, AB; 7Department of Microbiology, Immunology & Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB; 8Roy Romanow Provincial Lab, Saskatchewan Health Authority, Regina, SK; 9Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB; 10Provincial Laboratory for Public Health, Alberta Precision Laboratories, Edmonton, AB; 11Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB

P22
Verification of 2019 CLSI M100 Revised Ciprofloxacin Breakpoints for Pseudomonas aeruginosa using the Vitek® 2 N391 Gram-Negative AST Card
P Lagacé-Wiens1,2, M Stein1,2, P Pieroni1, HJ Adam1,2, CY Turenne1,2, A Walkty1,2, JA Karlowsky1,2
1Shared Health, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB

P23
Congenital SARS-CoV-2 infection in a pre-term neonate with viable virus from the placenta
JV Vayalumkal1, A Soraisham1, A Abou-Mehrem1, JV Dunn1, K Fonseca2, B Berenger2,3, MA Brundler1, Elaine Chan1, YCJ Lin1, D Evans1, JM Conly1
1Department of Pediatrics, University of Calgary, Calgary, AB; 2Alberta Public Health Laboratory, Calgary, AB; 3Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB; 4Department of Medicine, University of Calgary, Calgary, AB

P24
Comparative analysis of capillary versus venous blood for serologic detection of SARS-CoV-2 antibodies by rPOC lateral flow tests
T Pidduck, I Sekirov, M McLennan, P Levett, N Chahil, A Mak, E Carruthers, J Kustra, K Chu, F Burgess, L Willis, R Wada, R Blancaflor, M Krajden, MG Morshed
BCCDC Public Health Laboratory, Vancouver, BC

P25
Cefiderocol therapy in a Canadian urban academic centre: A new option to treat carbapenem-resistant gram-negative infections
C Ondro1, I Rajakumar1, S Bourassa-Blanchet1,2, A Ugarte-Torres1,2, J Salmon1,2
1Alberta Health Services, Calgary, AB; 2Department of Medicine, University of Calgary, Calgary, AB

P26
Survey results from a pilot antimicrobial stewardship prospective audit and feedback in general surgery
AJ Chan1, M Tsang1,2, BJ Langford3,4, M Downing1,2
1Unity Health Toronto, Toronto, ON; 2University of Toronto, Toronto, ON; 3Public Health Ontario, Toronto, ON; 4Hotel Dieu Shaver Health and Rehabilitation Centre, St. Catharines, ON

P27
Associated antibiotic use for community infections in British Columbia: a review of prescribing from 2000 – 2018
A Saatchi1, AM Morris2, DM Patrick3,4, J McCormack1, F Marra1,3
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC; 2Sinai Health System, University Health Network, and University of Toronto, Toronto, ON; 3British Columbia Centre for Disease Control, Vancouver, BC; 4School of Population and Public Health, University of British Columbia, Vancouver, BC

P28
The impact of a reported beta-lactam allergy on cefazolin administration in surgical prophylaxis: cefazolin is still best, but is it given?
HL Hoang1,2, KC Crick3, JZ Chen1,4, SR Fryters5, AU Chandran1, AW Tse-Chang6,7, DC Williams4,7, TW Myroniuk6, RO Yeung6, D Campbell-Scherer4, LM Saxinger1,4
1Division of Infectious Diseases, University of Alberta, Edmonton, AB; 2Covenant Health, Edmonton, AB; 3Physician Learning Program, Edmonton, AB; 4Alberta Health Services, Edmonton, AB; 5Pharmacy Services, Alberta Health Services, Edmonton, AB; 6Division of Pediatric Infectious Diseases, University of Alberta, Edmonton, AB; 7Department of Surgery, University of Alberta, Edmonton, AB

P29
A review of surgical antibiotic prophylaxis practice in adult urology procedures: opportunities for antimicrobial stewardship collaboration
JZ Chen1,2, HL Hoang1,3, KC Crick4, SR Fryters5, AU Chandran1, DC Williams6,7, T Myroniuk6, RO Yeung6, D Campbell-Scherer4, LM Saxinger1
1Division of Infectious Diseases, University of Alberta, Edmonton, AB; 2Covenant Health, Edmonton, AB; 3Physician Learning Program, Edmonton, AB; 4Alberta Health Services, Edmonton, AB; 5Pharmacy Services, Alberta Health Services, Edmonton, AB; 6Division of Surgery, University of Alberta, Edmonton, AB
**P30**  
Real-life experience with ceftobiprole in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry  
GG Zhanel1, J Kosar2, M Baxter1, R Dhami3,  
S Borgia4, N Irfan3, KS MacDonald3, G Dow5,  
P Lagace-Wiens2, M Dubé3, M Bergevin3,  
Y Keynan1, A Lee4, A Walkty1, JA Karlowsky1  
1University of Manitoba, Winnipeg, MB; 2Royal University Hospital, Saskatoon, SK; 3London Health Sciences Centre, London, ON; 4William Osler Health System, Brampton, ON; 5Hamilton Health Sciences Centre, Hamilton, ON; 6The Moncton Hospital, Moncton, NB; 7Sainte-Croix Hospital, Drummondville, QC; 8Cité de la Santé, Montréal, QC; 9Scarborough Health Network, Toronto, ON

**P31**  
An examination of selection, timing and duration of surgical prophylaxis for vascular procedures at a major Canadian vascular surgery centre  
HL Hoang1,2, GB Winkelhaar3,4, KC Crick5,  
JZ Chen1,6, SR Fryters2, AU Chandran3,  
DC Williams5,6, TW Myroniuk3, RO Yeung5,  
D Campbell-Scherer4, LM Saxinger1,6  
1Division of Infectious Diseases, University of Alberta, Edmonton, AB; 2Covenant Health, Edmonton, AB; 3Department of Surgery, University of Alberta, Edmonton, AB; 4Northern Alberta Vascular Centre, Edmonton, AB; 5Physician Learning Program, Edmonton, AB; 6Alberta Health Services, Edmonton, AB; 7Pharmacy Services, Alberta Health Services, Edmonton, AB

**P32**  
An audit of surgical antibiotic prophylaxis in orthopedic surgery with particular focus on duration of prophylaxis  
SR Fryters1, JZ Chen2, AU Chandran3, HL Hoang2,  
LM Saxinger4, KC Crick5, TW Myroniuk6,  
DC Williams5, RO Yeung5, D Campbell-Scherer4,  
AW Tse-Chang1  
1Pharmacy Services, Alberta Health Services, Edmonton, AB; 2Division of Infectious Diseases, University of Alberta, Edmonton, AB; 3Physician Learning Program, University of Alberta, Edmonton, AB; 4Alberta Health Services, Edmonton, AB; 5Physician Learning Program, Edmonton, AB; 6Division of Pediatric Infectious Diseases, University of Alberta, Edmonton, AB

**P33**  
An assessment of surgical antibiotic prophylaxis practices at a Canadian tertiary pediatric centre  
AW Tse-Chang1,2, KC Crick5, SR Fryters4,  
AU Chandran3,5, DC Williams2,6, TW Myroniuk3,  
RO Yeung1, D Campbell-Scherer4, LM Saxinger2,7  
1Division of Pediatric Infectious Diseases, University of Alberta, Edmonton, AB; 2Alberta Health Services, Edmonton, AB; 3Physician Learning Program, University of Alberta, Edmonton, AB; 4Pharmacy Services, Alberta Health Services, Edmonton, AB; 5University of Alberta, Edmonton, AB; 6Department of Surgery, University of Alberta, Edmonton, AB; 7Pharmacy Services, University of Alberta, Edmonton, AB; 8Division of Infectious Diseases, University of Alberta, Edmonton, AB

**P34**  
Comparison of contact precautions with routine practices for the prevention of vancomycin-resistant *Enterococcus* (VRE) infections in hospitals: The secret is in the routine  
H Glassman1, LE Burnes1, AC McFarlane1,2,  
AU Chandran1,2  
1University of Alberta, Edmonton, AB; 2Royal Alexandra Hospital, Edmonton, AB

**P35**  
What’s in a number? The value of titres as routine proof of immune protection  
NC Marshall1,2, AM Bailey1, LA Thompson1,  
JN Kanji1,2, CL Charlton1,2  
1Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; 2Alberta Provincial Public Health Laboratory, Edmonton, AB; 3Division of Infectious Diseases, Department of Medicine & Medical Microbiology/Immunology, Edmonton, AB

**P36**  
T King1, J Mah2, A Johnson2, M Fritzler1,3,  
B Yipp4, M Gillrie5,6  
1Department of Medicine, University of Calgary, Calgary, AB; 2Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, AB; 3Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, AB; 4Department of Critical Care, University of Calgary, Calgary, AB; 5Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB

**P37**  
Absence of transmission of NDM and OXA-48-like Carbapenemase Genes in a long-term care facility  
C Boedman1, N Gibson2, D Conrod2,  
CY Turenne3, D Alexander4, D Boyd1,  
L Mataseje1, M Mulvey1, JA Karlowsky1,  
M Blake1, J Embil1  
1University of Manitoba, Winnipeg, MB; 2Winnipeg Regional Health Authority, Winnipeg, MB; 3National Microbiology Laboratory, Winnipeg, MB; 4University of Manitoba, Winnipeg, MB
P38 Sensitivity of Cobas® 68/8800 SARS-CoV-2 test using gargoyle specimens with two different processing methods
P Benoit1, AC Labbé2,3, L Lalancette4, S Gagnon5, E Bonneau6, J Fafard6, S Beauchemin6, A Jetté6, S Tremblay6, K Filiautrat6, F Vancol-Fable6, F Coutlée1,2
1Université de Montréal, Montréal, QC; 2Centre Hospitalier de l’Université de Montréal, Montréal, QC; 3Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal, Montréal, QC; 4Centre Hospitalier Saint-Eustache, Saint-Eustache, QC; 5Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC

P39 Evaluation of the Q Score for assessing wound swab quality in a tertiary care centre
JD Forbes1, ST Clark1, LM Matukas1,2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; 2St. Michael’s Hospital, Unity Health Toronto, Toronto, ON

P40 Susceptibility patterns for Enterococcus spp. clinical isolates collected over a 14-year period
V Bugaj1, SAN Walker1,2, C Peragine2
1Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; 2Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON

P41 Maternal and fetal infection of non-typhoidal Salmonella during pregnancy
XX Li1,2, CK Lo1, JM Pernica3, P El-Helou1
1Division of Infectious Diseases, McMaster University, Hamilton, ON; 2Division of Medical Microbiology, McMaster University, Hamilton, ON; 3Division of Pediatric Infectious Diseases, McMaster University, Hamilton, ON

P42 Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian Leadership on Antimicrobial Real-life usage) Registry
GG Zhanel1, R Dhani1, M Baxter1, J Kosar1, C Cervera2, N Irfan3, R Zvona4, S Borgia5, JF Tessier6, G Dow7, R Ariano8, M Dubé1, M Savoie9, S Lutes10, A Walkey1, J Karlowsky1
1University of Manitoba, Winnipeg, MB; 2London Health Sciences Centre, London, ON; 3Royal University Hospital, Saskatoon, SK; 4University of Alberta, Edmonton, AB; 5Hamiton Health Sciences Centre, Hamilton, ON; 6The Ottawa Hospital, Ottawa, ON; 7William Osler Health System, Brampton, ON; 8CUSSS de l’Est-de-l’Île-de-Montréal, Montréal, QC; 9The Moncton Hospital, Moncton, NB; 10St. Boniface Hospital, Winnipeg, MB; 11Saint-Croix Hospital, Drummondville, QC; 12Queen Elizabeth Hospital, Charlottetown, PE

P43 Risks factors for severe outcomes in patients hospitalized with COVID-19 in a network of Canadian acute-care hospitals
R Mitchell1, K Baekyung Choi1, L Pelude1, W Rudnick1, J Brooks1, J Comeau2, JM Conly3, C Ellis1, J Ellison1, J Embil4, GA Evans5, GJ German6, BL Johnston7, JJohnstone8, KC Katz11, P Kibsey12, BE Lee13, MA Lefebvre14,15, Y Longtin16, A McGee19, D Mertz17, J Minion18, C Quach19, S Smith20, J Srigley21, P Stagg22, KN Suh23, A Wong24, N Thampi25, C Frenette15
1Public Health Agency of Canada, Ottawa, ON; 2IWK Health Centre, Halifax, NS; 3University of Calgary, Calgary, AB; 4The Moncton Hospital, Moncton, NB; 5Alberta Health Services, Calgary, AB; 6Health Sciences Centre, Winnipeg, MB; 7Kingston Health Sciences Centre, Kingston, ON; 8Queen Elizabeth Hospital, Charlottetown, PE; 9CHU Sainte-Justine, Montréal, QC; 10Sinai Health, Toronto, ON; 11North York General Hospital, Toronto, ON; 12Royal Jubilee Hospital, Victoria, BC; 13Sollery Children’s Hospital, Edmonton, AB; 14Montréal Children’s Hospital, Montréal, QC; 15McGill University Health Centre, Montréal, QC; 16SMBD-Jewish General Hospital, Montréal, QC; 17McMaster University and Hamilton Health Sciences, Hamilton, ON; 18Saskatchewan Health Authority, Regina, SK; 19CHU Sainte-Justine, Montréal, QC; 20University of Alberta Hospital, Edmonton, AB; 21BC Women's and Children's Hospital, Vancouver, BC; 22Western Memorial Hospital, Corner Brook, NL; 23The Ottawa Hospital, Ottawa, ON; 24Royal University Hospital, Saskatoon, SK; 25Children’s Hospital of Eastern Ontario, Ottawa, ON

P44 Reliability of E-gene Cycle Threshold (Ct) Values in Interpreting Duration of COVID-19 Infection
W Stokes1,2,3, J Kanji1,2,3, J Hu4,5, N Zelyas2,6, B Berenger7,8
1Alberta Public Health Laboratory, Alberta Precision Laboratories, Edmonton, AB; 2Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; 3Division of Infectious Diseases, Department of Medicine, Edmonton, AB; 4Department of Community Health Sciences, University of Calgary, Calgary, AB; 5Public Health, Alberta Health Services, Calgary, AB; 6Alberta Public Health Laboratory, Alberta Precision Laboratories, Edmonton, AB; 7Alberta Public Health Laboratory, Alberta Precision Laboratories, Calgary, AB; 8Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB

P45 Susceptibility of Pseudomonas aeruginosa to empiric therapy and alternative β-lactam antimicrobials in intensive care unit patients with respiratory tract infections in Canadian centers: SMART surveillance (2016-2019)
R El Ali1, M Gonzalez2, C Ghakis3, E O’Callaghan1
1Merck Canada Inc., Kirkland, QC; 2MSD, Madrid, Spain
P46 Nasopharyngeal expression of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) in children compared to adults within family clusters exposed to COVID-19
M Rubayet Hasan1,2, M Naseer Ahmad1, A Al Hashemi1, P Tang1,2
1Sidra Medicine, Doha, Qatar; 2Weill Cornell Medicine - Qatar, Doha, Qatar

P47 The association of frailty and outcomes among hospitalized COVID-19 patients in Toronto
A Shigayeva1, MK Andrew2, K Katz2,4, A Simor2,3, D Melady1, E Coomes3,6, B Coleman1,3, J Kwong3,7, A McGeer1,3, C Kandel1,3
1Sinai Health, Toronto, ON; 2Dalhousie University, Halifax, NS; 3University of Toronto, Toronto, ON; 4North York General Hospital, Toronto, ON; 5Sunnybrook Hospital, Toronto, ON; 6University Health Network, Toronto, ON; 7Public Health Ontario, Toronto, ON

P48 Real-life experience with IV fosfomycin in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry
GG Zhanel1, A Lee3, M Baxter1, N Irfan3, C Rotstein3, G GIRouard5, M Dube6, A Walkty1, JA Karlowsky3
1University of Manitoba, Winnipeg, MB; 2Scarborough Health Network, Toronto, ON; 3Hamilton Health Sciences Centre, Hamilton, ON; 4University Health Network, Toronto, ON; 5Centre Hospitalier Universitaire Dr-Georges-L.-Dumont, Montreal, NB; 6Sainte-Croix Hospital, Drummondville, QC

P49 Antimicrobial resistance trends of Staphylococcus aureus isolates collected from patients over 14 years
D Bedi1, SAN Walker1, C Peragine3
1Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; 2Department of Pharmacy, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto, ON

P50 Emergency department visits and readmission rates of patients discharged on OPAT: A retrospective observational study to identify predictors
JL Martinez-Cajas1, S McKenna2, B Alvarado-Llano1, E Wilson3, K Leifo1, S Perez-Peragine1, GA Evans1
1Queen’s University, Kingston, ON; 2Kingston Health Sciences Centre, Kingston, ON

P51 Prescribing pattern of restricted antimicrobials at a quaternary care academic hospital
RJ LeBlanc1, D Kabbani2, SW Smith2, KE Doucette2, C Lau3, S Bains3, K Fong1, J Stewart1, JZ Chen2
1University of British Columbia, Victoria, BC; 2University of Alberta, Edmonton, AB; 3Alberta Health Services, Edmonton, AB

P52 A quality audit of surgical antibiotic prophylaxis timing, redosing, and post-operative dosing practices in 5 hospital sites: The devil is in the details
LM Saxinger1,2; DC William3,4, KC Crick1, JZ Chen1,2, HL Hoang1,3, SR Fryters6, AU Chandran2, TW Myroniuk4, RO Yeung4, D Campbell-Scherer4
1Division of Infectious Diseases, University of Alberta, Edmonton, AB; 2Alberta Health Services, Edmonton, AB; 3Department of Surgery, University of Alberta, Edmonton, AB; 4Physician Learning Program, Edmonton, AB; 5Covenant Health, Edmonton, AB; 6Pharmacy Services, Alberta Health Services, Edmonton, AB

P53 Targeted plasma metabolomics method for the diagnosis of acute SARS-CoV-2
AT Le, M Wu, NA Phillips, PS Rajpurkar, M Sibai, CH Huang, MK Sahoo, J Mak, R Bowen, TM Cowan, BA Pinsky, CA Hogan
Stanford University, Palo Alto, CA, USA

P54 Lineage distributions of SARS-CoV-2 during the second wave in British Columbia
K Kamell1,2, S Russell1, H Sbini1,2, KA Macdonald4, D Fornika1, T Lee1, R Hickman1, J Tyson1, R Azana1, C Ng1, L Janc1, L Hoang1,2, N Prystajecky1,2
1British Columbia Centre for Disease Control, Vancouver, BC; 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 3School of Population and Public Health, University of British Columbia, Vancouver, BC; 4National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

P55 Assessment of fungal ITS PCR performance in formalin-fixed paraffin-embedded tissues
ST Clark1, YCW Yau1,2, A Campigotto1,2, SE Richardson1,2, F Gharabaghi3, M Tadros1,2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; 2Department of Pediatric Laboratory Medicine, Division of Microbiology, The Hospital for Sick Children, Toronto, ON
P56
Comparative genomics analysis of an IncR plasmid encoding blaNDM-1 from Enterobacter hormaechei involved in outbreak in Quebec
F Doualla-Bell1, DA Boyd2, D Roy3, K Yousfi4, I Bernaquez2, S Wong1, P Savard6, S Bekal1,4
1Laboratoire de Santé Publique du Québec, Institute National de Santé Publique du Québec, Ste Anne de Bellevue, Quebec, Quebec; 2Division of Enteric Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 3Laboratoire de Santé Publique du Québec, Institute National de Santé Publique du Québec, Ste Anne de Bellevue, QC; 4Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Montréal, QC; 5Département clinique de médecine des laboratoires OPTILAB-CHUM, Université de Montréal, Montréal, QC

P57
Yokenella regensburgei infection in an immunocompetent host
FH Al Mutawa
London Health Science Center, Pathology and Laboratory Medicine, London, ON; Department of Pathology and Laboratory Medicine. Schulich School of Medicine and Dentistry Western University, London, ON

P58
Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
I Sekirov1,2, M Petric1,2, E Carruthers1, D Lawrence1, N Chahil1, P Levett1,2, H Wood3, R Lindsay1, M Drebot1, M Krajden1,2, MG Morshed1,2
1British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC; 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 3National Microbiology Laboratory, Winnipeg, MB

P59
Necrotic myositis in an immunocompetent patient with persistent Bacillus cereus bacteremia and acute liver failure: A case report
A Cvetkovic, V Mokashi, K Woodward
McMaster University, Hamilton, ON

P60
How has antimicrobial use changed during the COVID-19 pandemic? A look at community antimicrobial use in Canada
G Smith, B Knight, D Greydanus, J Shurgold, J Brooks, D Gravel Tropper
Canadian Antimicrobial Resistance Surveillance System, Public Health Agency of Canada, Ottawa, ON

P61
Isolating Candida auris at Humber River Hospital: A comparative evaluation of media to develop a screening protocol for an emerging pathogen
C Morris, J Widla, J McLay, W Dubinski
Humber River Hospital, Toronto, ON

P62
WITHDRAWN

P63
Community antibiotic use at the population level during the SARS-CoV2 pandemic in British Columbia, Canada
AA Mamun1, A Saatchi2, M Xie1, H Lishman3, E Blondel-Hill4, F Marra2, DM Patrick1,3
1British Columbia Centre for Disease Control, Vancouver, BC; 2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC; 3School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC; 4Interior Health Authority, Kelowna, BC

P64
Prospective audit and feedback (PAF) in level II neonatal intensive care units (NICU) – Is it worth it?
K Alsager1, K Mponponsuo1, G Kerkerian1, A Krishnan2, D Dersch-Mills2, J Vayalumkal3, C Constantinescu3
1University of Calgary, Calgary, AB; 2Pharmacy Services, Alberta Health Services, Calgary, AB; 3Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, AB

P65
Validation of the triplex real-time RT-PCR assay for detection of Chikungunya, Dengue, and Zika viruses
B Hon1, E Grandbois1, MK Lee1, N Chahil1, MG Morshed1,2
1BC Centre for Disease Control - Public Health Laboratory, Vancouver, BC; 2University of British Columbia, Vancouver, BC

P66
Viral co-circulation during the COVID-19 pandemic: Broad respiratory testing to inform diagnostic stewardship
NC Marshall1,2, RM Kariyawasam1,2, N Zelyas1,2, MA Diggle1,2
1Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; 2Alberta Precision Laboratories – Public Health, Edmonton, AB
P67
The impact of ID consultation in patients with Enterococcus species bloodstream infection
BE Kula¹, TC Dingle², JZ Chen¹
¹University of Alberta, Edmonton, AB; ²Alberta Precision Laboratories, Edmonton, AB

P68
Comparison of the BD Phoenix CPO Detect Test and the NG-Test® CARBA-5 lateral flow assay for the detection of carbapenemase-producing organisms
L Li¹², M Sidhu³, L Kishi³, T Veddani³, G Arumugam³, M Hantid³, J Speakman³, M Charles¹²
¹Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³Provincial Health Services Authority, Vancouver, BC

P69
Performance of three different screening media for the detection of carbapenemase-producing organisms
L Li¹², M Sidhu³, L Kishi³, T Veddani³, G Arumugam³, M Hantid³, J Speakman³, M Charles¹²
¹Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³Provincial Health Services Authority, Vancouver, BC

P70
Comparison of two commercial broth microdilution methods for testing susceptibility to colistin in multi-drug resistant gram-negative organisms
L Li¹², J Grant¹², M Sidhu³, J Hsu³, J Hughes³, M Charles¹²
¹Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³Provincial Health Services Authority, Vancouver, BC

P71
An audit of surgical antibiotic prophylaxis in obstetrical/gynecological surgery
SR Fryters¹, JZ Chen², AU Chandran³, HL Hoang³, LM Saxinger⁴, KC Crick⁴, TW Myroniuks⁴, DC Williams⁵, RO Yeungs⁵, D Campbell-Scherers⁵
¹Pharmacy Services, Alberta Health Services, Edmonton, AB; ²Division of Infectious Diseases, University of Alberta, Edmonton, AB; ³Alberta Health Services, Edmonton, AB; ⁴Physician Learning Program, Edmonton, AB; ⁵Department of Surgery, University of Alberta, Edmonton, AB
**P75**

Evaluation of the Allplex™ 2019-nCoV assay for the detection of SARS-CoV-2 in a variety of clinical matrices

ST Clark¹, B Hazlett², S Isabel¹, A Aquino³, Q Liu², TT Mazzulli¹,², SM Poutanen¹,²,³

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; ²Department of Microbiology, University Health Network/Sinai Health System, Toronto, ON; ³Department of Medicine, University of Toronto, Toronto, ON

---

**P76**

Analysis of the performance of water gargle samples for SARS-CoV-2 detection by RT-PCR in a pediatric population

E Vallières¹,², J Fafard³, AC Labbé²,⁴,⁵, M Bergevin²,³, Z Laghdir¹, S Beauchemin⁴,⁵, M Desforges¹,²

¹CHU Sainte-Justine, Montréal, QC; ²Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université de Montréal, Montréal, QC; ³Laboratoire de Santé Publique du Québec, INSPQ, Ste-Anne-de-Bellevue, QC; ⁴CIUSSS de l’Est-de-l’Île-de-Montréal, Montréal, QC; ⁵CHUM, Montréal, QC; ⁶CISSS de Laval, Laval, QC

---

**P77**

Persistent Pandoraea sputorum bacteremia in a patient with extensive burns: a case report

V Weaver¹, M Clifford-Rashotte¹, V Lavergne², T Wong³

¹University of British Columbia, Vancouver, BC; ²Vancouver General Hospital, Vancouver, BC

---

**P78**

Validation of the EuroImmuno Anti-SARS-CoV-2 ELISA assay for detection of IgG and IgA antibodies in human breast milk

S Anwer¹, S Ismaïl², Y Yau³, S Unger¹,²,³, D O’Connor²,³,⁴, SM Poutanen¹,²

¹University Health Network/Sinai Health Department of Microbiology, Toronto, ON; ²University of Toronto, Toronto, ON; ³The Hospital for Sick Children, Toronto, ON; ⁴Mount Sinai Hospital, Toronto, ON

---

**P79**

Ct as an indicator of SARS-CoV-2 WGS success

KA Macdonald¹,²,³, C Fjell³, H Sbihi²,³, D Fornika², L Hoang²,³, N Prystajecky²,⁴

¹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ²BC Centre for Disease Control Public Health Laboratory, Provincial Health Services Agency, Vancouver, BC; ³School of Population and Public Health, The University of British Columbia, Vancouver, BC; ⁴Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC

---

**P80**

Sex-based differences in asexual organisms? Differences in the prevalence of antibiotic-resistance and multidrug-resistance in a retrospective sample of bacterial isolates collected from acute care male and female inpatients

D Peragine¹, C Peragine²

¹Department of Psychology, University of Toronto, Toronto, ON; ²Department of Pharmacy, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto, ON

---

**P81**

Expediting QC for COVID WGS analysis via Dashboards

KA MacDonald¹,², D Fornika², C Fjell³, H Sbihi²,³, L Hoang²,³, N Prystajecky²,⁴

¹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ²BC Centre for Disease Control Public Health Laboratory, Provincial Health Services Agency, Vancouver, BC; ³School of Population and Public Health, The University of British Columbia, Vancouver, BC; ⁴Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC

---

**P82**

The frequency of Carbapenemase-producing Enterobacterales during COVID-19

S Anwer¹, B Hazlett¹, M Kissoon¹, A McGeer¹,², TT Mazzulli¹,², SM Poutanen¹,²

¹University Health Network/Sinai Health Department of Microbiology, Toronto, ON; ²University of Toronto, Toronto, ON; ³University of Toronto, Toronto, ON

---

**P83**

Realization of theoretical savings following implementation of bioMerieux’s VITEK® MS for rapid microbial identification in patients with blood stream infections

GL Carr, W Gouliquer, A Skillen, D Welbourne, G Gamble

Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON
STUDENT E-POSTERS
On Demand starting Sunday, April 25
Poster Hall

SP01
Examination of the horizontal gene transfer dynamics of an integrative and conjugative element in *Histophilus somni*

MM Farghaly1, MM Nazari1, MF Hynes2, S Checkley1, N Rawlyk2, K Liljebjelke1
1Department of Ecosystem and Public Health, Faculty of Veterinary Medicine, University of Calgary, Calgary, AB; 2Department of Biological Science, Faculty of Science, Calgary, AB

SP02
Antiviral use among Canadian children hospitalized for influenza, 2010-2019

K Mehta1, S Morris3, JA Bettinger5, W Vaudry4, T Jadavji6, SA Halperin1, C Bancej7, M Sadarangani3,8, N Dendukuri1,9, J Papenburg1,8,10,11
1Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC; 2Division of Pediatric Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON; 3Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC; 4Division of Pediatric Infectious Diseases, Department of Paediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, AB; 5Section of Infectious Diseases, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB; 6Division of Pediatric Infectious Diseases, Department of Paediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, AB; 7Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montréal, QC; 8Division of Pediatric Infectious Diseases, Department of Pediatrics, Montréal Children's Hospital, McGill University Health Centre, Montréal, QC; 9Division of Microbiology, Department of Clinical Laboratory Medicine, McGill University Health Centre, Montréal, QC

SP03
Jamestown Canyon and snowshoe hare virus seroprevalence in New Brunswick

J Mincer1, S Materniak2, K Dimitrova3, H Wood4, M Iranpour2, A Dibernardo3, C Loomer3, MA Drebot3, R Lindsay3, D Webster1,2,4
1Dalhousie Medicine New Brunswick, Dalhousie University, Saint John, NB; 2Horizon Health Network, Saint John, NB; 3National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 4Division of Infectious Diseases, Saint John Regional Hospital, Saint John, NB

SP04
Evaluation of the identification of *Staphylococcus pseudintermedius* from human wound cultures

HL Bibby1, KL Brown1,2
1Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB; 2Department of Medicine, University of Calgary, Calgary, AB
SP05
Getting to the heart of the matter: A case of Bartonella quintana endocarditis with serological cross-reactivity to Coxiella burnetii
H Glassman1, SC Houston1, A Alrohimi1, P Dobrowolski1, M Oosthuizen2, JZ Chen1
1University of Alberta, Edmonton, AB; 2Tamarack Medical Clinic, Cranbrook, BC

SP06
The difference between age- and weight-based approach to determine adequate volume of blood culture volume drawn from pediatric patients
EYH Yeung1,2, NMA Le Saux3
1University of Ottawa, Ottawa, ON; 2Eastern Ontario Regional Laboratory Association, Ottawa, ON; 3Children's Hospital of Eastern Ontario, Ottawa, ON

SP07
Invasive mould disease in fatal COVID-19: A systematic review of autopsies
BE Kula1, CJ Clancy2, M Hong Nguyen2, IS Schwartz2
1University of Alberta, Edmonton, AB; 2University of Pittsburgh, Pittsburgh, PA, USA

SP08
Risk factors and protective measures for healthcare worker infection during highly infectious viral respiratory epidemics: a systematic review and meta-analysis
C Tian1, O Lovrics2, A Vaisman3, K Chin4, G Tomlinson5, Y Lee6, M Englesakis7, M Parotto8, M Singh9,10
1Faculty of Medicine, University of Toronto, Toronto, ON; 2Faculty of Medicine, McMaster University, Hamilton, ON; 3Infection Prevention and Control, University Health Network, Toronto, ON; 4Department of Anesthesia and Pain Management, University Health Network, Toronto, ON; 5Department of Medicine, University Health Network, Toronto, ON; 6Division of General Surgery, McMaster University, Hamilton, ON; 7Information Specialist, Library & Information Services, University Health Network, Toronto, ON; 8Department of Anesthesia and Pain Management, Women’s College Hospital, Toronto, ON

SP09
Recovering influenza genomes from wild bird habitats for better avian flu surveillance
KS Kuchinski1, J Duan1, M Coombe1,2, C Himsworth1,2, W Hsiao1, N Prystajecky1,3
1University of British Columbia, Vancouver, BC; 2BC Ministry of Agriculture, Abbotsford, BC; 3BC Centre for Disease Control, Vancouver, BC

SP10
A nine-month evaluation of a prenatal universal screening program for Hepatitis C (HCV) in Alberta, Canada
LA Thompson1, CL Charlton1,2
1Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; 2Alberta Precision Laboratories, AHS-Edmonton, Edmonton, AB

SP11
Evaluating the efficacy of the DMC40 defined microbial community on Clostridiodes difficile infection
KS Douchant1,2, M Guzman1, S Mei He1, C Noordhof1, S Vanner1,2, G Gloor3, E Allen-Vercoe4, E Petrof1,2, PM Sheth1,2,5
1Gastrointestinal Disease Research Unit (GIDRU), Queen’s University, Kingston, ON; 2Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON; 3Department of Biochemistry, University of Western Ontario, London, ON; 4Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON; 5Division of Microbiology, Kingston Health Sciences Centre, Kingston, ON

SP12
Clinical characterization of string-test positive Klebsiella pneumoniae invasive disease compared to string-test negative K. pneumoniae invasive disease controls
IF McNamara1,2, KR Barker3, B Hazlett1, TT Mazzulli1,4, SM Poutanen1,4
1University Health Network/Sinai Health System, Toronto, ON; 2University of Utah School of Medicine, SLC, Utah, USA; 3Trillium Health Partners, Mississauga, ON; 4University of Toronto, Toronto, ON

SP13
Challenges of pediatric prospective audit and feedback (PAF) during the COVID-19 pandemic
K Alsager1, D Dersch-Mills2, J Vayalumkal3,4, C Constantinescu2
1University of Calgary, Calgary, AB; 2Pharmacy Services, Alberta Health Services, Calgary, AB; 3Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, AB; 4Infection Prevention and Control, Alberta Health Services, Calgary, AB; 5Pediatric Infectious Disease, Clinical Assistant Professor, University of Calgary, Calgary, AB

SP14
Impact of compliance with inpatient antibiotic audit and feedback on patient and economic outcomes
S London1, G McDonald2
1Memorial University of Newfoundland, St. John’s, NL; 2Eastern Health, St. John’s, NL
SP15
A retrospective cohort comparison of outpatient antibiotic use for seniors, across British Columbia & Ontario, from 2000 to 2018
A Saatchi1, J Reid2, M Povitz3, S Shariff3, M Silverman4, AM Morris5, DM Patrick6,7, F Marra1,6
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC; 2Institute for Clinical Evaluative Sciences, Western University, London, ON; 3Department of Medicine, University of Calgary, Calgary, AB; 4Faculty of Medicine, University of Western Ontario, London, ON; 5Sinai Health System, University Health Network, and University of Toronto, Toronto, ON; 6British Columbia Centre for Disease Control, Vancouver, BC; 7School of Population and Public Health, University of British Columbia, Vancouver, BC

SP16
Extensive stomatitis caused by herpes simplex virus 1 in a small cell lung cancer patient undergoing chemoradiotherapy: a case report and literature review
CKL Lo1, AE Sumner2, CKF Lo3, S Haider1
1Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, ON; 2Department of Medicine, Queen’s University, Kingston, ON; 3Department of Medicine, University of British Columbia, Vancouver, BC

SP17
Evaluation of human antibodies of the immunoglobulin class A and G against SARS-CoV-2 in serum: A provincial public health laboratory experience
L Gilbert1,2, R Needle1,2, G Zahariadis1,2, Y Yu1,3, H Dalton-Kenny1, RS Russel1, PP Wang2,4, C Donovan2,5, S Hookey1, L Jiao1,3
1Newfoundland and Labrador Public Health Microbiology Laboratory, Department of Laboratory Medicine, Eastern Health, St. John’s, NL; 2Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL; 3Discipline of Laboratory Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL; 4Dalhousie School of Public Health, University of Toronto, Toronto, ON; 5Eastern Health, St. John’s, NL

SP18
Antibiotic usage in a Neonatal Intensive Care Unit (NICU) before and after the introduction of an antibiotic stewardship intervention
M Hirtle-Lewis, R Chafe, N Bridger, J Emberley, C Foo
Janeway Children’s Health and Rehabilitation Centre, St John’s, NL

SP19
Are we over-reacting to cutaneous diphtheria? A 10-year review of public health investigations and diphtheria toxin testing across Alberta
NC Marshall1,2, M Baxi1, C MacDonald1,2, C Sikora3, GJ Tyrrell1,2
1Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; 2Alberta Provincial Public Health Laboratory, Edmonton, AB; 3Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; 4Alberta Health Services, AB

SP20
Exploring next-generation sequencing limits of detection for antimicrobial resistance genes in genomes and metagenomic samples
AM Rooney1,2, AR Raphenya3, RG Melano1,4, DR MacFadden5, N Yee2, AG McArthur1, PHH Schneeberger6, B Coburn1,2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; 2Toronto General Research Institute, University Health Network, Toronto, ON; 3D Braley Centre for Antibiotic Discovery, M.G. DeGroote Institute for Infectious Disease Research, and the Department of Biochemistry and Biomedical Science, McMaster University, Hamilton, ON; 4Public Health Ontario Laboratory, Toronto, ON; 5Ottawa Hospital Research Institute, Ottawa, ON; 6Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland

SP21
Dimensions of poverty as risk factors for antimicrobial resistant organisms in Canada: A structured narrative review
T King1, R Schindler1,2, S Chavda1, JM Conly1,3,4,5
1Department of Medicine, University of Calgary, Calgary, AB; 2Provincial Population and Public Health, Alberta Health Services, Calgary, AB; 3Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB; 4O’Brien Institute for Public Health, University of Calgary, Calgary, AB; 5Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB
SP22
Cost-effectiveness analysis of the BioFire FilmArray Blood Culture Identification (BCID) panel molecular rapid diagnostic test compared to conventional methods for identification of Escherichia coli bloodstream infections
K Mponponso1, J Lea2,3,4, E Spackman1,5, R Somayaji1,2,3,5,6, D Gregson1,6,7,8, E Rennert-May1,2,3,5,6
1Department of Medicine, University of Calgary, Calgary, AB; 2Department of Community Health Sciences, University of Calgary, Calgary, AB; 3Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB; 4Infection Prevention and Control, Alberta Health Services, Calgary, AB; 5O’Brien Institute for Public Health, University of Calgary and Alberta Health Services, Calgary, AB; 6Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB; 7Alberta Precision Laboratories, University of Calgary, Calgary, AB

SP23
Management and outcome of febrile neutropenia in admitted presumed immunocompetent patients with suspected viral illness
E Morin1, C Corriiveau-Bourque2, J Foulds3
1Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alberta, Edmonton, AB; 2Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alberta, Edmonton, AB; 3Division of Pediatric Hospital Medicine, Department of Pediatrics, University of Alberta, Edmonton, AB

SP24
Assays to measure the impact of previous coronavirus infection on the immune response generated from SARS-CoV-2 infection and vaccination
FF Li1, A Liu1, E Gibbs1, G Tanunliong1, J Duan1,4, N Prystajecky1,4, M Krajden1,4, MG Morshed1,4, S Ganti1, N Cashman1, I Sekirov1,4, A Jassem1,4
1Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 2Experimental Medicine, University of British Columbia, Vancouver, BC; 3Diavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC; 4BC Centre for Disease Control, Vancouver, BC; 5Microbiology, Infectious Diseases and Immunology, University of Montréal, Montréal, QC

SP25
Endocarditis due to Bartonella quintana, the etiological agent of trench fever, among four individuals linked to the same homeless shelter
C Boodman1, T Wuerz1, P Lagacé-Wiens1
University of Manitoba, Winnipeg, MB

SP26
The genomic epidemiology of Carbapenemase-Producing Enterobacteriales (CPE) at a healthcare facility in Toronto, Ontario, Canada
A Jamal1, L Mataseje2, V Williams3, J Leis4, N Tijet4, S Zittermann4, R Melano4, M Mulvey5, K Katz5, V Allen6, A McGeer1,6
1University of Toronto, Toronto, ON; 2National Microbiology Laboratory, Winnipeg, MB; 3Sunnybrook Health Sciences Centre, Toronto, ON; 4Public Health Ontario Laboratory, Toronto, ON; 5National Microbiology Laboratory, Toronto, ON; 6Sunnybrook Health System, Toronto, ON

SP27
An imperative of flu vaccination: A systematic review of the clinical characteristics of influenza-COVID-19 co-infection
K Varshney1,2,3, R Kyada3, J Adalbert1,4
1Vancouver Coastal Health, Vancouver, BC; 2School of Medicine, Deakin University, Geelong, VIC, Australia; 3College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA; 4Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

SP28
A dramatic shift in the nasal microbiota of individuals infected with SARS-CoV-2
E Moslinger1,2, K Tozer3, K Douchant1,4, C Nordhoff1,2, SM He1,2, H Wong5, P Sheth1,2,3,5
1Gastrointestinal Disease Research Unit (GIDRU), Department of Medicine, Queen’s University, Kingston, ON; 2Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON; 3Faculty of Health Sciences, Queen’s University, Kingston, ON; 4Division of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON; 5Division of Microbiology, Kingston Health Sciences Centre, Kingston, ON

SP29
Empiric antimicrobial prescribing, microbiology, and antibiotic stewardship needs in early breast cancer patients in the emergency department
V Bugaj1, M Guirguis2, C DeAngelis1,4, C Peragine3
1Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; 2Faculty of Pharmacy, University of Waterloo, Waterloo, ON; 3Department of Pharmacy, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto, ON; 4Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON

SP30
Impact of automated WASPLab incubation on plate contamination and turnaround times for cerebrospinal fluids
XX Li1,2, M Gaskin3, C Main1,2,3
1Division of Medical Microbiology, McMaster University, Hamilton, ON; 2Division of Infectious Diseases, McMaster University, Hamilton, ON; 3Hamilton Regional Laboratory Medicine Program, Hamilton, ON
SP31
COVID-19 Associated Pulmonary Aspergillosis (CAPA) in critically ill patients: A systematic review
RM Kariyawasam1,2, TC Dingle1,2, W Sligl1,4, BE Kula1, IS Schwartz3
1Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB; 2Alberta Precision Laboratories-Public Health, Edmonton, AB; 3Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB; 4Department of Critical Care Medicine, University of Alberta, Edmonton, AB

SP32
Comparative analysis of SARS-CoV-2 diagnosis specificity and sensitivity using three sampling methods by quantitative PCR and droplet digital PCR
E Collins1,2, K Shir-Mohammadi1, JJ Jia1, HC Birnboim1, C Cooper1,2, MA Langlois1
1University of Ottawa, Ottawa, ON; 2Ottawa Hospital Research Institute, Ottawa, ON; 3deltaDNA Biosciences Inc, Toronto, ON

SP33
Community acquired MRSA pericarditis in a pregnant female
O Mourad, D Koh, P El-Helou
McMaster University, Hamilton, ON

SP34
In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to Lefamulin, a new Pleuromutilin
RM Taylor1, J A Karlowsky1,2, MR Baxter1, Hj Adam1,2, A Walky1,2, P Lagacé-Wiens1,2, L Mandell1,2, GG Zhanel1
1Max Rady College of Medicine, University of Manitoba, Winnipeg, MB; 2Shared Health Manitoba, Winnipeg, MB; 3University of Toronto, Toronto, ON

SP35
Atypical diagnosis of typical HUS with off-site molecular stool testing
P Gregory1, E MacAdam1, G Patriquin1,2
1Dalhousie University, Halifax, NS; 2Nova Scotia Health, Halifax, NS

SP36
Comparative evaluation of four vaporized hydrogen peroxide-based systems to decontaminate N95 respirators
ST Clark1, H Ng2, G Wu1, D Jain1, R Kandel1,4, TT Mazzulli1,2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; 2Department of Microbiology, University Health Network/Sinai Health System, Toronto, ON; 3Medical Engineering, University Health Network, Toronto, ON; 4Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON

SP37
Clinical characteristics, management and outcomes of splenic abscesses
R Mangat, J Gray, T Louie
University of Rochester Medical Center, Rochester, NY, USA

SP38
Prevention of COVID-19 in internally displaced persons camps in Eastern Democratic Republic of the Congo: a mixed-methods study
QN Mian1, KM Claude2, MS Serge3, KK Alexis3, MT Hawkes1,4,5,6,7
1Department of Pediatrics, University of Alberta, Edmonton, AB; 2Department of Medicine, Université Catholique du Graben, Butembo, Democratic Republic of the Congo; 3Department of Ophthalmology, Université Catholique du Graben, Butembo, Democratic Republic of the Congo; 4Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB; 5School of Public Health, University of Alberta, Edmonton, AB; 6Stollery Science Lab, University of Alberta, Edmonton, AB; 7Women and Children’s Health Research Institute, University of Alberta, Edmonton, AB

SP39
Comprehensive genomic insight into Shiga-toxin producing Escherichia coli (STEC) to understand virulence and detect priority STEC serotypes
K Yousfi1,2, RH Khan1, C Landgraff3, K Lanyon3, I Bernaquez1, F Doualla-Bell1, D Roy1, S Bekal1
1Laboratoire de Santé Publique du Québec, Ste Anne de Bellevue, QC; 2Université de Montréal, Montréal, QC; 3Division of Enteric Diseases, National Microbiology Laboratory, Winnipeg, MB

SP40
WITHDRAWN

SP41
Sapovirus molecular epidemiology in Canadian children: Insights from a 4-year province wide prospective study
X Ding1, R Zhuo1, L Jasper1, J Xie2, S Freedman2, Y Wu1, L Chui3, B Lee1, S Ali1, X Pang3
1University of Alberta, Edmonton, AB; 2Department of Pediatrics and Section of Pediatric Emergency Medicine, University of Calgary, Calgary, AB; 3Alberta Precision Laboratories, Edmonton, AB

SP42
Overuse of piperacillin-tazobactam in patients admitted to medicine wards
E MacAdam1, P Gregory1, P Bonnar1,2
1Dalhousie University, Halifax, NS; 2Nova Scotia Health, Halifax, NS
**SP43**

**Treatment of bloodstream infections caused by ceftriaxone-resistant E. coli, P. mirabilis and Klebsiella species: review of extended-spectrum beta-lactamase production and patient outcomes in a low prevalence setting**

S Smith¹, H Al Sidairi², EK Reid³, C Smith³, G Patriquin⁴, P Bonnar⁴, R Davidson⁵

¹IWK Health Centre, Halifax, NS; ²Laboratory Services Department, Ibi Referral Hospital, Ibi, Oman; ³Dalhousie University, Halifax, NS; ⁴Nova Scotia Health, Halifax, NS; ⁵Department of Pathology and Laboratory Medicine, Division of Microbiology, Nova Scotia Health, Halifax, NS

**SP44**

**Prediction of cytomegalovirus antiviral resistance using next-generation sequencing in a clinical virology laboratory**

S D Chorlton¹, G Ritchie¹, T Lawson¹, E McLachlan², MG Romney³, N Matic³, CF Lowe¹

¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ²Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver, BC; ³National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

**SP45**

**WITHDRAWN**

**SP46**

**Oral administration of defined microbial community (DCM-18) protects against Clostridioides difficile infection in mice**

M Guzman¹, C Noordhoff², SM He³, E Allen-Vercoe¹, D Hurlbut¹, G B. Gloer³, SJ Vanner¹, EO Petrof³, PM Sheth¹,4,6

¹Gastrointestinal Disease Research Unit (GIDRU), Department of Medicine, Queen’s University, Kingston, ON; ²Gastrointestinal Disease Research Unit (GIDRU), Department of Medicine, Queen’s University, Kingston, ON; ³Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON; ⁴Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON; ⁵Department of Biochemistry, University of Western Ontario, London, ON; ⁶Division of Microbiology, Kingston Health Sciences Center, Kingston, ON

**SP47**

**Quantifying the effect on case numbers of public health intervention in Canada’s COVID-19 pandemic**

MT Crocker¹, P Loudovski¹, W Wobeser¹, ², V Hoeppner³

¹Queen’s University, Department of Public Health Sciences, Kingston, ON; ²Queen’s University, Department of Biomedical and Molecular Sciences, Kingston, ON; ³University of Saskatchewan, Department of Medicine, Saskatoon, SK

**SP48**

**Decreasing the incidence of external ventricular drain infections: Has standardizing insertion and management practices made a difference?**

A Cvetkovic, A Shroff, C Main, D Mertz

McMaster University, Hamilton, ON

**SP49**

**Creation of a cumulative antibiogram for local intensive care units reveals significant resistance**

DB Duncan¹, D Yamamura¹,², D Mertz¹,², N Irfan¹,²

¹McMaster University, Hamilton, ON; ²Hamilton Health Sciences, Hamilton, ON

**SP50**

**Evaluating correlates of viral shedding patterns in SARS-CoV-2 patients**

KM Tozer¹,², E Moslinger¹,³, J Lam¹, A Khalil¹, P Beddoe¹, K Douchant¹,², H Wong¹, P Sheth¹,²,³,⁶

¹Gastrointestinal Disease Research Unit (GIDRU), Queen’s University, Kingston, ON; ²Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON; ³Pathology and Molecular Medicine, Queen’s University, Kingston, ON; ⁴Department of Medicine, Queen’s University, Kingston, ON; ⁵Center for Advanced Computing, Queen’s University, Kingston, ON; ⁶Division of Microbiology, Kingston Health Sciences Center, Kingston, ON

**SP51**

**Fever and runny nose in a healthy adult patient: An interesting case of bacterial meningitis with normal CSF parameters**

C Guenther¹, W Slig¹, G Shumilak¹

¹University of Saskatchewan, Saskatoon, SK; ²University of Alberta, Edmonton, AB

**SP52**

**Acceptability of self-collected samples for COVID-19 diagnosis in outpatients**

E Finlayson-Trick¹, P Tilley¹,², GN Al-Rawahi¹,², JA Srigley¹,², JM Pernica³, LMN Hoang¹,⁴, DM Goldfarb¹,²

¹University of British Columbia, Vancouver, BC; ²Division of Medical Microbiology, BC Children’s Hospital & BC Women’s Hospital & Health Centre, Vancouver, BC; ³Department of Pediatrics, McMaster University, Hamilton, ON; ⁴BC Centre for Disease Control, Vancouver, BC
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abou-Mehrem, Ayman</td>
<td>P23</td>
</tr>
<tr>
<td>Adalbert, Jenna</td>
<td>SP27</td>
</tr>
<tr>
<td>Adam, Heather</td>
<td>B01, P16, P18, P19, P22, SP34</td>
</tr>
<tr>
<td>Afra, Kevin</td>
<td>P14</td>
</tr>
<tr>
<td>Ahmad, Muneera</td>
<td>P46</td>
</tr>
<tr>
<td>Al Hashemi, Alaa</td>
<td>P46</td>
</tr>
<tr>
<td>Al Mutawa, Fatimah</td>
<td>P57</td>
</tr>
<tr>
<td>Al-Rawahi, Ghada</td>
<td>D02, P03, SP52</td>
</tr>
<tr>
<td>Alemayheu, Gelila</td>
<td>C01</td>
</tr>
<tr>
<td>Alexander, David</td>
<td>P05, P37</td>
</tr>
<tr>
<td>Alexis, Kahindo</td>
<td>SP38</td>
</tr>
<tr>
<td>Ali, Samina</td>
<td>SP41</td>
</tr>
<tr>
<td>Allen, Vanessa</td>
<td>P05, SP26</td>
</tr>
<tr>
<td>Allen-Vercoe, Emma</td>
<td>SP11, SP46</td>
</tr>
<tr>
<td>Alloo, Javed</td>
<td>D01</td>
</tr>
<tr>
<td>Alrohimi, Anas</td>
<td>SP05</td>
</tr>
<tr>
<td>Alsager, Khaled</td>
<td>D04, P64, SP13</td>
</tr>
<tr>
<td>Alvarado-Llano, Beatriz</td>
<td>P01, P50</td>
</tr>
<tr>
<td>Andrew, Melissa</td>
<td>P47</td>
</tr>
<tr>
<td>Anwer, Shaista</td>
<td>P78, P82</td>
</tr>
<tr>
<td>Aquino, Ana</td>
<td>P75</td>
</tr>
<tr>
<td>Ariano, Rob</td>
<td>P42</td>
</tr>
<tr>
<td>Arumugam, Gnanalaksni</td>
<td>P68, P69</td>
</tr>
<tr>
<td>Avery, Brent</td>
<td>P05</td>
</tr>
<tr>
<td>Azana, Robert</td>
<td>P54</td>
</tr>
<tr>
<td>Baekyung Choi, Kelly</td>
<td>P43</td>
</tr>
<tr>
<td>Bailey, Ashley-Nicole</td>
<td>P35</td>
</tr>
<tr>
<td>Bains, Serena</td>
<td>P20, P51</td>
</tr>
<tr>
<td>Balamohan, Archana</td>
<td>C04</td>
</tr>
<tr>
<td>Banoe, Christina</td>
<td>SP02</td>
</tr>
<tr>
<td>Barakauskas, Vitte</td>
<td>E02</td>
</tr>
<tr>
<td>Barker, Kevin</td>
<td>P13, SP12</td>
</tr>
<tr>
<td>Barton, Michelle</td>
<td>C04, P74</td>
</tr>
<tr>
<td>Baxi, Maulik</td>
<td>SP19</td>
</tr>
<tr>
<td>Baxter, Melanie</td>
<td>P30, P42, P48, SP34</td>
</tr>
<tr>
<td>Bayliss, Ann</td>
<td>P74</td>
</tr>
<tr>
<td>Beaucourni, Catherine</td>
<td>P06</td>
</tr>
<tr>
<td>Beauchemin, Stéphanie</td>
<td>E03, P38, P73, P76</td>
</tr>
<tr>
<td>Beddoe, Paige</td>
<td>SP50</td>
</tr>
<tr>
<td>Bedi, Dylan</td>
<td>P49</td>
</tr>
<tr>
<td>Bekal, Sagdia</td>
<td>B04, P05, P56, SP39</td>
</tr>
<tr>
<td>Benoit, Patrick</td>
<td>A04, P38</td>
</tr>
<tr>
<td>Berenger, Byron</td>
<td>P23, P44</td>
</tr>
<tr>
<td>Bergevin, Marco</td>
<td>P30, P76</td>
</tr>
<tr>
<td>Bernaquez, Isabelle</td>
<td>B04, P56, SP39</td>
</tr>
<tr>
<td>Bestman-Smith, Julie</td>
<td>E03</td>
</tr>
<tr>
<td>Bettinger, Julie</td>
<td>SP02</td>
</tr>
<tr>
<td>Bharat, Amrita</td>
<td>P05</td>
</tr>
<tr>
<td>Bibby, Helen</td>
<td>SP04</td>
</tr>
<tr>
<td>Birnboim, H. Chaim</td>
<td>SP32</td>
</tr>
<tr>
<td>Bitnun, Ari</td>
<td>P74</td>
</tr>
<tr>
<td>Black, Emily</td>
<td>P15</td>
</tr>
<tr>
<td>Blake, Molly</td>
<td>P37</td>
</tr>
<tr>
<td>Blancaflor, Rosemarie</td>
<td>P24</td>
</tr>
<tr>
<td>Blondel-Hill, Edith</td>
<td>P63</td>
</tr>
<tr>
<td>Bonnar, Paul</td>
<td>D03, SP42, SP43</td>
</tr>
<tr>
<td>Bonneau, Eric</td>
<td>P38</td>
</tr>
<tr>
<td>Boodman, Carl</td>
<td>P37, SP25</td>
</tr>
<tr>
<td>Borgia, Sergio</td>
<td>P30, P42</td>
</tr>
<tr>
<td>Boucher, Valérie</td>
<td>E03</td>
</tr>
<tr>
<td>Bourassa-Blanchette, Samuel</td>
<td>P25</td>
</tr>
<tr>
<td>Bowen, Raffick</td>
<td>P53</td>
</tr>
<tr>
<td>Bowes, Jennifer</td>
<td>C04, P74</td>
</tr>
<tr>
<td>Boyd, David</td>
<td>P03, P37, P56</td>
</tr>
<tr>
<td>Bradley, John</td>
<td>C04</td>
</tr>
<tr>
<td>Brenes-Chacon, Helena</td>
<td>P74</td>
</tr>
<tr>
<td>Brennan, Christopher</td>
<td>P02</td>
</tr>
<tr>
<td>Bridger, Natalie</td>
<td>SP18</td>
</tr>
<tr>
<td>Brooks, James</td>
<td>D02, P43, P60</td>
</tr>
<tr>
<td>Brown, Kevin</td>
<td>D01</td>
</tr>
<tr>
<td>Brown, Kristen</td>
<td>SP04</td>
</tr>
<tr>
<td>Brundler, Marie-Anne</td>
<td>P23</td>
</tr>
<tr>
<td>Bryce, Elizabeth</td>
<td>B02</td>
</tr>
<tr>
<td>Bugaj, Victoria</td>
<td>P40, SP29</td>
</tr>
<tr>
<td>Bullard, Jared</td>
<td>P74</td>
</tr>
<tr>
<td>Burak, Kelly</td>
<td>P21</td>
</tr>
<tr>
<td>Burgess, Fred</td>
<td>P24</td>
</tr>
<tr>
<td>Burns, Laura</td>
<td>A02, P34</td>
</tr>
<tr>
<td>Campbell-Scherer, Denise</td>
<td>P28, P29, P31, P32, P33, P52, P71</td>
</tr>
<tr>
<td>Campigotto, Aaron</td>
<td>P13, P55</td>
</tr>
<tr>
<td>Caron, Louise Josée</td>
<td>P73</td>
</tr>
<tr>
<td>Carr, Georgia</td>
<td>P83</td>
</tr>
<tr>
<td>Carruthers, Erin</td>
<td>P24, P58</td>
</tr>
<tr>
<td>Carson, Carolee</td>
<td>P05</td>
</tr>
<tr>
<td>Cashman, Neil</td>
<td>SP24</td>
</tr>
<tr>
<td>Cervera, Carlos</td>
<td>P20, P42</td>
</tr>
<tr>
<td>Cheafe, Roger</td>
<td>SP18</td>
</tr>
<tr>
<td>Chahil, Navdeep</td>
<td>P24, P58, P65</td>
</tr>
<tr>
<td>Chan, April</td>
<td>P26</td>
</tr>
<tr>
<td>Chan, Elaine</td>
<td>P23</td>
</tr>
<tr>
<td>Chandran, A. Uma</td>
<td>P28, P29, P31, P32, P34, P33, P52, P71</td>
</tr>
<tr>
<td>Charles, Marthe</td>
<td>B02, E02, P68, P69, P70</td>
</tr>
<tr>
<td>Charlton, Carmen</td>
<td>P35, SP10</td>
</tr>
<tr>
<td>Chauva, Swati</td>
<td>SP21</td>
</tr>
<tr>
<td>Chedek, Sylvia</td>
<td>SP01</td>
</tr>
<tr>
<td>Chen, Justin</td>
<td>A02, P20, P28, P29, P31, P32, P51, P52, P67, P71, SP05</td>
</tr>
<tr>
<td>Chien, Tammy</td>
<td>P03</td>
</tr>
<tr>
<td>Chin, Ki Jinn</td>
<td>SP08</td>
</tr>
<tr>
<td>Choi, Kelly</td>
<td>D02</td>
</tr>
<tr>
<td>Chorion, Samuel</td>
<td>SP44</td>
</tr>
<tr>
<td>Chow, Blanda</td>
<td>D02</td>
</tr>
<tr>
<td>Chu, Ken</td>
<td>P24</td>
</tr>
<tr>
<td>Chui, Linda</td>
<td>P05, SP41</td>
</tr>
<tr>
<td>Clancy, Cornelius</td>
<td>SP07</td>
</tr>
<tr>
<td>Clark, Shawn</td>
<td>P39, P55, P75, SP36</td>
</tr>
<tr>
<td>Claude, Kaserae</td>
<td>SP38</td>
</tr>
<tr>
<td>Claveau, David</td>
<td>P06</td>
</tr>
<tr>
<td>Clifford-Rashotte, Matthew</td>
<td>P77</td>
</tr>
<tr>
<td>Coburn, Bryant</td>
<td>SP20</td>
</tr>
<tr>
<td>Coleman, Brenda</td>
<td>P47</td>
</tr>
<tr>
<td>Collet, Jun</td>
<td>D02</td>
</tr>
<tr>
<td>Collins, Erin</td>
<td>SP32</td>
</tr>
<tr>
<td>Comeau, Jeannette</td>
<td>D02, P15, P43</td>
</tr>
<tr>
<td>Conly, John</td>
<td>P17, P23, P43, SP21</td>
</tr>
<tr>
<td>Conrod, Davenna</td>
<td>P37</td>
</tr>
<tr>
<td>A</td>
<td>D</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Constantinescu, Cora</td>
<td>D04, P64, SP13</td>
</tr>
<tr>
<td>Cook, Darrel</td>
<td>E02</td>
</tr>
<tr>
<td>Cooke, Suzette</td>
<td>P74</td>
</tr>
<tr>
<td>Coombe, Michelle</td>
<td>SP09</td>
</tr>
<tr>
<td>Coomes, Eric</td>
<td>P47</td>
</tr>
<tr>
<td>Cooper, Curtis</td>
<td>SP32</td>
</tr>
<tr>
<td>Corriiveau-Bourke, Catherine</td>
<td>SP23</td>
</tr>
<tr>
<td>Coutlée, François</td>
<td>A04, P38</td>
</tr>
<tr>
<td>Cowan, Tina</td>
<td>P53</td>
</tr>
<tr>
<td>Cox, Graham</td>
<td>P05</td>
</tr>
<tr>
<td>Crick, Katelynn</td>
<td>P28, P29, P31, P32, P33, P52, P71</td>
</tr>
<tr>
<td>Crocker, Matthew</td>
<td>SP47</td>
</tr>
<tr>
<td>Cuarte, Audrey</td>
<td>P03</td>
</tr>
<tr>
<td>Cvetkovic, Anna</td>
<td>P59, SP48</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daignault, Danielle</td>
<td>P05</td>
<td>Fafard, Judith</td>
</tr>
<tr>
<td>Daley, Peter</td>
<td>SP14</td>
<td>Farghaly, Mai</td>
</tr>
<tr>
<td>Dalton-Kenny, Hedy</td>
<td>SP17</td>
<td>Farshait, Nataly</td>
</tr>
<tr>
<td>Daneman, Nick</td>
<td>A01, D01</td>
<td>Fearing, Margaret</td>
</tr>
<tr>
<td>Davidson, Ross</td>
<td>SP43</td>
<td>Feng, Lillian</td>
</tr>
<tr>
<td>Davies, H. Dele</td>
<td>C04</td>
<td>Filiatrault, Karine</td>
</tr>
<tr>
<td>Davis, lan</td>
<td>D02, D03</td>
<td>Finlayson-Trick, Emma</td>
</tr>
<tr>
<td>DeAngelis, Carlo</td>
<td>SP29</td>
<td>Fjell, Chris</td>
</tr>
<tr>
<td>Deckert, Anne</td>
<td>SP02</td>
<td>Fong, Karen</td>
</tr>
<tr>
<td>Delage, Gilles</td>
<td>P02, P04</td>
<td>Fonseca, Kevin</td>
</tr>
<tr>
<td>Dengdikuri, Nandini</td>
<td>SP02</td>
<td>Foo, Cheryl</td>
</tr>
<tr>
<td>Dersch-Mills, Deonne</td>
<td>P64, SP13</td>
<td>Forbes, Jessica</td>
</tr>
<tr>
<td>Desforges, Marc</td>
<td>P76</td>
<td>Fornika, Dan</td>
</tr>
<tr>
<td>Devine, Dana</td>
<td>P12</td>
<td>Foulds, Jessica</td>
</tr>
<tr>
<td>Devlin, Megan</td>
<td>C04</td>
<td>Fournier, Stéphanie</td>
</tr>
<tr>
<td>Dewan, Tammie</td>
<td>D02, P30, P42</td>
<td>Freedman, Stephen</td>
</tr>
<tr>
<td>Dhalliwal, Inderdeep</td>
<td>P07</td>
<td>Freire, Dolores</td>
</tr>
<tr>
<td>Dhalliwal, Suk</td>
<td>P03</td>
<td>Frenette, Charles</td>
</tr>
<tr>
<td>Dhami, Rita</td>
<td>SP03</td>
<td>Friedman, Steven</td>
</tr>
<tr>
<td>Diaz Pallarez, Carolina</td>
<td>C03</td>
<td>Fritzler, Marvin</td>
</tr>
<tr>
<td>Dibernardo, Antonio</td>
<td>SP03</td>
<td>Fryters, Susan</td>
</tr>
<tr>
<td>Diggle, Mathew</td>
<td>P66</td>
<td>Fung, Christopher</td>
</tr>
<tr>
<td>Dillon, Jo-Anne</td>
<td>C02</td>
<td></td>
</tr>
<tr>
<td>Dimitrova, Kristina</td>
<td>SP03</td>
<td></td>
</tr>
<tr>
<td>Ding, Xiaofeng</td>
<td>SP41</td>
<td></td>
</tr>
<tr>
<td>Dingle, Tanis</td>
<td>B03, P67, SP31</td>
<td></td>
</tr>
<tr>
<td>Dixit, Devika</td>
<td>P17</td>
<td></td>
</tr>
<tr>
<td>Dobrovolski, Peter</td>
<td>SP05</td>
<td></td>
</tr>
<tr>
<td>Donovan, Catherine</td>
<td>SP17</td>
<td></td>
</tr>
<tr>
<td>Doualla-Bell, Florence</td>
<td>B04, E03, P56, P73, SP39</td>
<td></td>
</tr>
<tr>
<td>Doucette, Karen</td>
<td>P20, P51</td>
<td></td>
</tr>
<tr>
<td>Douchant, Katya</td>
<td>SP11, SP28, SP50</td>
<td></td>
</tr>
<tr>
<td>Dow, Gordon</td>
<td>P30, P42</td>
<td></td>
</tr>
<tr>
<td>Downing, Mark</td>
<td>P26</td>
<td></td>
</tr>
<tr>
<td>Drexels, Michael</td>
<td>P12, P58, SP03</td>
<td></td>
</tr>
<tr>
<td>Drews, Steven</td>
<td>E01, P02, P04, P12</td>
<td></td>
</tr>
<tr>
<td>Du, Tim</td>
<td>D02</td>
<td></td>
</tr>
<tr>
<td>Duan, Jun</td>
<td>SP09, SP24</td>
<td></td>
</tr>
<tr>
<td>Dube, Maxime</td>
<td>P30, P42, P48</td>
<td></td>
</tr>
<tr>
<td>Dubinski, William</td>
<td>P61</td>
<td></td>
</tr>
<tr>
<td>Dufresne, Simon Frédéric</td>
<td>P06</td>
<td></td>
</tr>
<tr>
<td>Dumaresq, Jeannot</td>
<td>P73</td>
<td></td>
</tr>
<tr>
<td>Duncan, D. Brody</td>
<td>SP49</td>
<td></td>
</tr>
<tr>
<td>Dunn, Jessica</td>
<td>P23</td>
<td></td>
</tr>
<tr>
<td>Dupuis, Alan</td>
<td>P12</td>
<td></td>
</tr>
<tr>
<td>Dwellow, Rachel</td>
<td>P74</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fafard, Judith</td>
<td>E03, P38, P73, P76</td>
<td></td>
</tr>
<tr>
<td>Farghaly, Mai</td>
<td>SP01</td>
<td></td>
</tr>
<tr>
<td>Farshait, Nataly</td>
<td>P13</td>
<td></td>
</tr>
<tr>
<td>Fearing, Margaret</td>
<td>P02</td>
<td></td>
</tr>
<tr>
<td>Feng, Lillian</td>
<td>P03</td>
<td></td>
</tr>
<tr>
<td>Filiatrault, Karine</td>
<td>P38</td>
<td></td>
</tr>
<tr>
<td>Finlayson-Trick, Emma</td>
<td>SP52</td>
<td></td>
</tr>
<tr>
<td>Fjell, Chris</td>
<td>P79, P81</td>
<td></td>
</tr>
<tr>
<td>Fong, Karen</td>
<td>P20, P51</td>
<td></td>
</tr>
<tr>
<td>Fonseca, Kevin</td>
<td>P21, P23</td>
<td></td>
</tr>
<tr>
<td>Foo, Cheryl</td>
<td>P05, SP18</td>
<td></td>
</tr>
<tr>
<td>Forbes, Jessica</td>
<td>P39</td>
<td></td>
</tr>
<tr>
<td>Fornika, Dan</td>
<td>P54, P79, P81</td>
<td></td>
</tr>
<tr>
<td>Foulds, Jessica</td>
<td>SP23</td>
<td></td>
</tr>
<tr>
<td>Fournier, Stéphanie</td>
<td>P73</td>
<td></td>
</tr>
<tr>
<td>Freedman, Stephen</td>
<td>SP41</td>
<td></td>
</tr>
<tr>
<td>Freire, Dolores</td>
<td>C04</td>
<td></td>
</tr>
<tr>
<td>Frenette, Charles</td>
<td>D02, P43</td>
<td></td>
</tr>
<tr>
<td>Friedman, Steven</td>
<td>E04</td>
<td></td>
</tr>
<tr>
<td>Fritzler, Marvin</td>
<td>P36</td>
<td></td>
</tr>
<tr>
<td>Fryters, Susan</td>
<td>P28, P29, P31, P32, P33, P52, P71</td>
<td></td>
</tr>
<tr>
<td>Fung, Christopher</td>
<td>P21</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gagnon, Simon</td>
<td>A04, P38</td>
<td></td>
</tr>
<tr>
<td>Gamble, Gregory</td>
<td>P83</td>
<td></td>
</tr>
<tr>
<td>Gant, Soren</td>
<td>SP7</td>
<td></td>
</tr>
<tr>
<td>Garber, Gary</td>
<td>D01</td>
<td></td>
</tr>
<tr>
<td>Gaskin, Mark</td>
<td>SP03</td>
<td></td>
</tr>
<tr>
<td>Gaudreau, Christiane</td>
<td>B04</td>
<td></td>
</tr>
<tr>
<td>Gaussens, Amaury</td>
<td>P04</td>
<td></td>
</tr>
<tr>
<td>German, Gregory</td>
<td>P05, P43</td>
<td></td>
</tr>
<tr>
<td>Ghakis, Christiane</td>
<td>P45</td>
<td></td>
</tr>
<tr>
<td>Gharabaghli, Farhad</td>
<td>P55</td>
<td></td>
</tr>
<tr>
<td>Gibbs, Ebrima</td>
<td>SP24</td>
<td></td>
</tr>
<tr>
<td>Gibson, Natalie</td>
<td>P37</td>
<td></td>
</tr>
<tr>
<td>Gilbert, Laura</td>
<td>SP17</td>
<td></td>
</tr>
<tr>
<td>Gill, Peter</td>
<td>P74</td>
<td></td>
</tr>
<tr>
<td>Gillrie, Mark</td>
<td>P36</td>
<td></td>
</tr>
<tr>
<td>Girardin, Roxie</td>
<td>P12</td>
<td></td>
</tr>
<tr>
<td>Girouard, Gabriel</td>
<td>P48</td>
<td></td>
</tr>
<tr>
<td>Glassman, Heather</td>
<td>P34, SP05</td>
<td></td>
</tr>
<tr>
<td>Glier, Melissa</td>
<td>P72</td>
<td></td>
</tr>
<tr>
<td>Gloor, Gregory</td>
<td>SP11, SP46</td>
<td></td>
</tr>
<tr>
<td>Gobeille Paré, Sarah</td>
<td>E03</td>
<td></td>
</tr>
<tr>
<td>Goldfarb, David</td>
<td>SP52</td>
<td></td>
</tr>
<tr>
<td>Gonzalez, Marcela</td>
<td>P45</td>
<td></td>
</tr>
<tr>
<td>Gouliquer, Wendy</td>
<td>P83</td>
<td></td>
</tr>
<tr>
<td>Grandbois, Ella</td>
<td>P65</td>
<td></td>
</tr>
<tr>
<td>Grandjean-Lapierre, Simon</td>
<td>A04</td>
<td></td>
</tr>
<tr>
<td>Grant, Jennifer</td>
<td>P70</td>
<td></td>
</tr>
<tr>
<td>Gratrix, Jennifer</td>
<td>C03</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E</th>
<th>E</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eksteen, Eduard</td>
<td>P08</td>
<td></td>
</tr>
<tr>
<td>El Ali, Radwan</td>
<td>P45</td>
<td></td>
</tr>
</tbody>
</table>

Author Index | 45
<table>
<thead>
<tr>
<th>Name</th>
<th>Volumes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gravel Tropper, Denise</td>
<td>P60</td>
</tr>
<tr>
<td>Gray, Jonathan</td>
<td>SP37</td>
</tr>
<tr>
<td>Gregoire, Yves</td>
<td>P02</td>
</tr>
<tr>
<td>Gregory, Peter</td>
<td>SP35, SP42</td>
</tr>
<tr>
<td>Gregson, Daniel</td>
<td>SP22</td>
</tr>
<tr>
<td>Greydanus, Drew</td>
<td>P60</td>
</tr>
<tr>
<td>Grimshaw, Jeremy</td>
<td>D01</td>
</tr>
<tr>
<td>Guenther, Catherine</td>
<td>SP51</td>
</tr>
<tr>
<td>Guinan, Kimberly</td>
<td>P06</td>
</tr>
<tr>
<td>Guirguis, Michael</td>
<td>SP29</td>
</tr>
<tr>
<td>Guzman, Mabel</td>
<td>SP11, SP46</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Haghighi Aski, Behzad</td>
<td>P74</td>
</tr>
<tr>
<td>Haider, Shariq</td>
<td>SP16</td>
</tr>
<tr>
<td>Haldane, David</td>
<td>P05</td>
</tr>
<tr>
<td>Halperin, Scott</td>
<td>SP02</td>
</tr>
<tr>
<td>Han, Guanghong</td>
<td>D02</td>
</tr>
<tr>
<td>Han, Ray</td>
<td>P72</td>
</tr>
<tr>
<td>Hansen, Bettina</td>
<td>A01</td>
</tr>
<tr>
<td>Hantid, Mellichie</td>
<td>H68, H69</td>
</tr>
<tr>
<td>Hardy, Isabelle</td>
<td>A04</td>
</tr>
<tr>
<td>Harrigan, Richard</td>
<td>A04</td>
</tr>
<tr>
<td>Hasan, Mohammad</td>
<td>P46</td>
</tr>
<tr>
<td>Hassan, Kaz</td>
<td>P13</td>
</tr>
<tr>
<td>Hassan Khan, Rufaida</td>
<td>SP39</td>
</tr>
<tr>
<td>Hawes, Gordon</td>
<td>P02</td>
</tr>
<tr>
<td>Hawkes, Michael</td>
<td>SP38</td>
</tr>
<tr>
<td>Hayden, Althea</td>
<td>E02</td>
</tr>
<tr>
<td>Hazlett, Bryn</td>
<td>E04, P75, P82, P12</td>
</tr>
<tr>
<td>He, Shu-Mei</td>
<td>SP28, SP46</td>
</tr>
<tr>
<td>Hernandez-de Mezerville, Marcela</td>
<td>P74</td>
</tr>
<tr>
<td>Hickman, Rebecca</td>
<td>P54</td>
</tr>
<tr>
<td>Himsworth, Chelsea</td>
<td>SP09</td>
</tr>
<tr>
<td>Hirtle-Lewis, Marika</td>
<td>SP18</td>
</tr>
<tr>
<td>Hizon, Romeo</td>
<td>D02</td>
</tr>
<tr>
<td>Hoang, Holly</td>
<td>P28, P29, P31, P32, P52, P71</td>
</tr>
<tr>
<td>Hoang, Linda</td>
<td>B02, P03, P05, P04, P79, P81, SP42</td>
</tr>
<tr>
<td>Hoeppner, Vernon</td>
<td>SP47</td>
</tr>
<tr>
<td>Hogan, Catherine</td>
<td>P53</td>
</tr>
<tr>
<td>Hon, Benjamin</td>
<td>P65</td>
</tr>
<tr>
<td>Hookey, Sandy</td>
<td>SP17</td>
</tr>
<tr>
<td>Hornby, Laura</td>
<td>P04</td>
</tr>
<tr>
<td>Hosseini, Sandra</td>
<td>P14</td>
</tr>
<tr>
<td>Hota, Susy</td>
<td>D02</td>
</tr>
<tr>
<td>Houston, Stanley</td>
<td>SP05</td>
</tr>
<tr>
<td>Hsiao, William</td>
<td>SP09</td>
</tr>
<tr>
<td>Hsu, Joanne</td>
<td>P70</td>
</tr>
<tr>
<td>Hu, Jia</td>
<td>P21, P44</td>
</tr>
<tr>
<td>Huang, Chun Hong</td>
<td>P53</td>
</tr>
<tr>
<td>Hughes, Josie</td>
<td>P70</td>
</tr>
<tr>
<td>Hurlbut, David</td>
<td>SP46</td>
</tr>
<tr>
<td>Hynes, Michael</td>
<td>SP01</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Ioudovski, Paul</td>
<td>SP47</td>
</tr>
<tr>
<td>Iranpour, Mahmood</td>
<td>SP03</td>
</tr>
<tr>
<td>Irfan, Neal</td>
<td>P30, P42, P48, SP49</td>
</tr>
<tr>
<td>Irwin, Rebecca</td>
<td>P05</td>
</tr>
<tr>
<td>Isabel, Sandra</td>
<td>P75</td>
</tr>
<tr>
<td>Ismail, Samantha</td>
<td>P78</td>
</tr>
<tr>
<td>Ivankovich-Escoto, Gabriela</td>
<td>P74</td>
</tr>
<tr>
<td>Ivers, Noah</td>
<td>D01</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Jacob-Wagner, Mariève</td>
<td>E03</td>
</tr>
<tr>
<td>Jadavji, Taj</td>
<td>SP02</td>
</tr>
<tr>
<td>Jain, Devika</td>
<td>SP36</td>
</tr>
<tr>
<td>Jamal, Alainna</td>
<td>SP26</td>
</tr>
<tr>
<td>Jameson, Peter</td>
<td>P17</td>
</tr>
<tr>
<td>Jansen, Brad</td>
<td>B03</td>
</tr>
<tr>
<td>Janz, Loretta</td>
<td>P54</td>
</tr>
<tr>
<td>Jasper, Luong</td>
<td>SP41</td>
</tr>
<tr>
<td>Jassem, Agatha</td>
<td>E02, SP24</td>
</tr>
<tr>
<td>Jenkinson, Richard</td>
<td>A01</td>
</tr>
<tr>
<td>Jetté, Angie</td>
<td>P38</td>
</tr>
<tr>
<td>Jia, Jian-Jun</td>
<td>SP32</td>
</tr>
<tr>
<td>Jiao, Lei</td>
<td>SP17</td>
</tr>
<tr>
<td>Johnson, Andrew</td>
<td>P36</td>
</tr>
<tr>
<td>Johnston, B. Lynn</td>
<td>P43</td>
</tr>
<tr>
<td>Johnstone, Jennie</td>
<td>D02, P43</td>
</tr>
<tr>
<td>Joo, Pil</td>
<td>A03</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Kabbani, Dima</td>
<td>P20, P51</td>
</tr>
<tr>
<td>Kamelian, Kimia</td>
<td>P54</td>
</tr>
<tr>
<td>Kandel, Christopher</td>
<td>A01, P47</td>
</tr>
<tr>
<td>Kandel, Rita</td>
<td>SP36</td>
</tr>
<tr>
<td>Kanji, Jamil</td>
<td>P21, P35, P44</td>
</tr>
<tr>
<td>Kariyawasam, Ruwandi</td>
<td>P08, P66, SP31</td>
</tr>
<tr>
<td>Kishi, Leane</td>
<td>B02, P68, P69</td>
</tr>
<tr>
<td>Kim, Teagan</td>
<td>P36, SP21</td>
</tr>
<tr>
<td>King, Teagan</td>
<td>P69</td>
</tr>
<tr>
<td>Kissoon, Melissa</td>
<td>P82</td>
</tr>
<tr>
<td>Knight, Braden</td>
<td>P60</td>
</tr>
<tr>
<td>Knoppers, Bartha</td>
<td>P02</td>
</tr>
<tr>
<td>Koh, Deborah</td>
<td>SP33</td>
</tr>
<tr>
<td>Kosar, Justin</td>
<td>P30, P42</td>
</tr>
<tr>
<td>Kowalewska-Grochowska, Kinga</td>
<td>A02, P08</td>
</tr>
<tr>
<td>Krajden, Mel</td>
<td>E02, P24, P58, SP24</td>
</tr>
<tr>
<td>Krishnan, Anish</td>
<td>P64</td>
</tr>
<tr>
<td>Kuchinski, Kevin</td>
<td>SP09</td>
</tr>
<tr>
<td>Kula, Brittany</td>
<td>P67, SP07, SP31</td>
</tr>
<tr>
<td>Kustra, Jesse</td>
<td>P24</td>
</tr>
<tr>
<td>Kwong, Jeffrey</td>
<td>P44</td>
</tr>
<tr>
<td>Kuyat, Ruvin</td>
<td>SP27</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Labbé, Annie-Claude</td>
<td>E03, P38, P73, P76</td>
</tr>
<tr>
<td>Lachaine, Jean</td>
<td>P06</td>
</tr>
<tr>
<td>Lagacé-Wiens, Philippe</td>
<td>B01, P16, P18, P19, P22, P30, SP25, SP34</td>
</tr>
<tr>
<td>Lagdir, Zineb</td>
<td>P76</td>
</tr>
<tr>
<td>Lalancette, Linda</td>
<td>P38</td>
</tr>
<tr>
<td>Lam, Jasmine</td>
<td>SP56</td>
</tr>
<tr>
<td>Landes, Megan</td>
<td>E04</td>
</tr>
<tr>
<td>Landgraff, Chrystal</td>
<td>SP39</td>
</tr>
<tr>
<td>Landry, Liette</td>
<td>P06</td>
</tr>
<tr>
<td>Lang, Amanda</td>
<td>C02, P21</td>
</tr>
<tr>
<td>Langford, Bradley</td>
<td>D01, P26</td>
</tr>
<tr>
<td>Langley, Joanne</td>
<td>D02</td>
</tr>
<tr>
<td>Langlois, Marc-André</td>
<td>SP32</td>
</tr>
<tr>
<td>Author Name</td>
<td>Page(s)</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Lanyon, Katrina</td>
<td>SP39</td>
</tr>
<tr>
<td>Lau, Cecilia</td>
<td>P20, P51</td>
</tr>
<tr>
<td>Lautermich, Janell</td>
<td>P74</td>
</tr>
<tr>
<td>Lavallée, Christian</td>
<td>E03</td>
</tr>
<tr>
<td>Law, Sampson</td>
<td>P77</td>
</tr>
<tr>
<td>Lawrence, David</td>
<td>P21</td>
</tr>
<tr>
<td>Lawson, Tanya</td>
<td>P58</td>
</tr>
<tr>
<td>Laxer, Ron</td>
<td>SP44</td>
</tr>
<tr>
<td>Le Saux, Nicole</td>
<td>P74</td>
</tr>
<tr>
<td>Le, Anthony</td>
<td>C04</td>
</tr>
<tr>
<td>Leal, Jeanine</td>
<td>SP22</td>
</tr>
<tr>
<td>LeBlanc, Jason</td>
<td>D03</td>
</tr>
<tr>
<td>LeBlanc, Ryan</td>
<td>P51</td>
</tr>
<tr>
<td>Lee, Anna</td>
<td>P30</td>
</tr>
<tr>
<td>Lee, Bonita</td>
<td>D02, P43</td>
</tr>
<tr>
<td>Lee, Claire</td>
<td>C01</td>
</tr>
<tr>
<td>Le, Min-Kuang</td>
<td>P65</td>
</tr>
<tr>
<td>Lee, Tracy</td>
<td>P54</td>
</tr>
<tr>
<td>Lee, Yung</td>
<td>SP08</td>
</tr>
<tr>
<td>Lefebvre, Marie-Astrid</td>
<td>C04, P43, P74</td>
</tr>
<tr>
<td>Leisso, Kirk</td>
<td>D01</td>
</tr>
<tr>
<td>Lémieux, Camille</td>
<td>E04</td>
</tr>
<tr>
<td>Le, Jerome</td>
<td>C02</td>
</tr>
<tr>
<td>Le, Aurora</td>
<td>D01</td>
</tr>
<tr>
<td>Leung, Valerie</td>
<td>E02, P24</td>
</tr>
<tr>
<td>Levet, Paul</td>
<td>P04</td>
</tr>
<tr>
<td>Lewin, Antoine</td>
<td>SP24</td>
</tr>
<tr>
<td>Li, Fang Fang</td>
<td>B02, P68</td>
</tr>
<tr>
<td>Li, Lisa</td>
<td>P41, SP30</td>
</tr>
<tr>
<td>Li, Xena</td>
<td>P01</td>
</tr>
<tr>
<td>Liljebjelke, Karen</td>
<td>P12</td>
</tr>
<tr>
<td>Lin, James</td>
<td>P58, SP03</td>
</tr>
<tr>
<td>Lishman, Hannah</td>
<td>P63</td>
</tr>
<tr>
<td>Liu, Aaron</td>
<td>SP24</td>
</tr>
<tr>
<td>Liu, Qin</td>
<td>P16</td>
</tr>
<tr>
<td>Lo, Calvin</td>
<td>P12</td>
</tr>
<tr>
<td>Lo, Carson</td>
<td>SP16</td>
</tr>
<tr>
<td>London, Sydney</td>
<td>P41, SP16</td>
</tr>
<tr>
<td>Longtin, Yves</td>
<td>SP14</td>
</tr>
<tr>
<td>Loomer, Courtney</td>
<td>D02, P43</td>
</tr>
<tr>
<td>Louie, Ted</td>
<td>SP03</td>
</tr>
<tr>
<td>Lovinsky, Reena</td>
<td>SP37</td>
</tr>
<tr>
<td>Lovrics, Olivia</td>
<td>P13</td>
</tr>
<tr>
<td>Lowe, Christopher</td>
<td>SP08</td>
</tr>
<tr>
<td>Lutes, Sarah</td>
<td>SP44</td>
</tr>
<tr>
<td>Mccormack, James</td>
<td>P04</td>
</tr>
<tr>
<td>McFarlane, Alexandra</td>
<td>SP02</td>
</tr>
<tr>
<td>McKeen, Susan</td>
<td>SP01</td>
</tr>
<tr>
<td>McLachlan, Elizabeth</td>
<td>P01</td>
</tr>
<tr>
<td>Mclay, Jahn</td>
<td>P12</td>
</tr>
<tr>
<td>McLennan, Meghan</td>
<td>SP24</td>
</tr>
<tr>
<td>McManus, Janet</td>
<td>SP03</td>
</tr>
<tr>
<td>Mcnair, Jacqueline</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP12</td>
</tr>
<tr>
<td>Mcnair, ALLIE</td>
<td>SP44</td>
</tr>
</tbody>
</table>
O'Brien, Sheila E01, P02, P04 P45 P78 E02 P25 SP05
O'Callaghan, Emma P45
O'Connor, Deborah P78
Olmstead, Andrea E02
Ondro, Christine P25
Oosthuizen, Madeline SP05

Pambrun, Chantale E01, P12 SP41 P74, SP02 C02 P05 SP08 C04 P27, P63, SP15 SP35, SP43 D02, P43
Pang, Xiaoli SP41
Papenburg, Jesse P74
Pare, Nicholas P78
Patrick, David C04
Patriquin, Glenn SP07, SP31
Pelude, Linda P58
Penny, Ryan SP11, SP46 P09 P80 P01, P50 C01, P41, SP52 P58 SP16, P18, P19, P22 B04 A03 SP11, SP28, SP46, P50
Pinnell, Rhiannan P53 P13 A04 P02 E04, P75, P78, P82, SP12 SP15 P54, P72, P79, P81 P04 P05 A03 C04 SP20 SP01 D03, SP43 SP15 SP22 P74 P21 P13 P55 SP44
Pinnell, Rhiannan

Q
Quach, Caroline

Rajakumar, Irina
Rajpurkar, Pranav
Ramsay, Tim
Ranger, Adriana
Raphenya, Amogelang
Rawlyk, Neil
Reid, Emma
Reid, Jennifer
Reid-Smith, Richard
Rennert-May, Elissa
Restivo, Lea
Rice, Chris
Richardson, David
Richardson, Susan
Ritchie, Gordon

Roberts, Ashley P74
Robinson, Joan C04, P74
Rock, Gary P04 SP44
Romney, Marc P20
Rooney, Ashley P06, P48
Rotstein, Coleman SP44
Roy, David B04, P56, SP39
Rudnick, Wallis P43
Russell, Rodney SP17
Russell, Shannon P54


Saaetchi, Ariana P27, P63, SP15
Sadarangani, Manish P74, SP02
Saeed, Sahar E01
Sahoo, Malay P53
Salmon, Joanne P25
Sandila, Navjot D03
Sapir-Pichhadze, Ruth P04
Savar, Patrice P56
Savoie, Michel P42

Science, Michelle D02, P15
Sekirov, Inna E02, P24, P58, SP24
Serge, Muyisa SP38
Shariif, Salimah SP15
Sheth, Prameet SP11, SP28, SP46, P50

Shigayeva, Altnyay P47
Shing, Emily D01
Shir-Mohammadi, Khatereh SP32
Shroff, Anjali SP48
Shumilak, Geoffrey SP51
Shurgold, Jayson P60
Sibai, Mamoudou P53
Sidhu, Munjao P68, P69, P70
Sikora, Christopher SP19
Silva, Anada D02
Silverman, Michael D01, SP15
Simms, Janet E02
Simor, Andrew P47
Simpson, Christy P02
Singh, Ameeta C03
Singh, Mandeep SP08
Skar, Gwenn C04
Skillet, Aaron P83
Slayter, Kathryn P15

Sligl, Wendy SP31, SP51
Smith, Carolyn SP43
Smith, Glensy SP60
Smith, Shawn A02, P20, P43, P51
Smyczek, Petra SP43
Snedeker, Kate C03
Somayaji, Ranjani SP22
Soraiham, Amuchou P23
Soriano-Fallas, Alejandra SP43
Spackman, Eldon SP22
Speakman, Jane P68, P69
Spicer, Erin P07
St-Hilaire, Manon E03
<table>
<thead>
<tr>
<th>Author index</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stagg, Paula</td>
<td>B01, P16, P18, P19, P22, B01, P16, P18, P19, P22, P30, P42, P48, SP34</td>
</tr>
<tr>
<td>Stein, Markus</td>
<td>P44</td>
</tr>
<tr>
<td>Stewart, Jackson</td>
<td>P20, P51</td>
</tr>
<tr>
<td>Stokes, William</td>
<td>C03</td>
</tr>
<tr>
<td>Strong, David</td>
<td>P17</td>
</tr>
<tr>
<td>Suh, Kathryn</td>
<td>D02, P43, B02</td>
</tr>
<tr>
<td>Sumner, Alison</td>
<td>SP16</td>
</tr>
<tr>
<td>Swanston, Claire</td>
<td>B02</td>
</tr>
<tr>
<td>Tadros, Manal</td>
<td>P55</td>
</tr>
<tr>
<td>Taljaard, Monica</td>
<td>D01</td>
</tr>
<tr>
<td>Tang, Patrick</td>
<td>P46</td>
</tr>
<tr>
<td>Tang, Vincent</td>
<td>B02</td>
</tr>
<tr>
<td>Tanunliong, Guadalein</td>
<td>SP24</td>
</tr>
<tr>
<td>Tapalski, Dmitry</td>
<td>P09, P11</td>
</tr>
<tr>
<td>Taylor, Robert</td>
<td>P35, SP10</td>
</tr>
<tr>
<td>Tchao, Christine</td>
<td>SP08</td>
</tr>
<tr>
<td>Tessier, Jean-Francois</td>
<td>SP02</td>
</tr>
<tr>
<td>Thomp, L Alexa</td>
<td>SP34</td>
</tr>
<tr>
<td>Tilley, Peter</td>
<td>SP28, SP50</td>
</tr>
<tr>
<td>Timberlake, Kathryn</td>
<td>P74</td>
</tr>
<tr>
<td>Timoskova, Elena</td>
<td>P03, SP52</td>
</tr>
<tr>
<td>Tomlinson, George</td>
<td>P15</td>
</tr>
<tr>
<td>Tousignant, Francine</td>
<td>P11</td>
</tr>
<tr>
<td>Touzer, Kyla</td>
<td>SP08</td>
</tr>
<tr>
<td>Trajman, Adriana</td>
<td>P17</td>
</tr>
<tr>
<td>Tremblay, Cécile</td>
<td>SP38</td>
</tr>
<tr>
<td>Tremblay, Sonia</td>
<td>P72</td>
</tr>
<tr>
<td>Tsang, Frankie</td>
<td>P03, SP52</td>
</tr>
<tr>
<td>Tsang, Melanie</td>
<td>P15</td>
</tr>
<tr>
<td>Tse-Chang, Alena</td>
<td>P11</td>
</tr>
<tr>
<td>Tsekerkos, Stephen</td>
<td>SP08</td>
</tr>
<tr>
<td>Turcotte, Christine</td>
<td>SP28, SP32, P33</td>
</tr>
<tr>
<td>Turnbull, LeeAnn</td>
<td>P73</td>
</tr>
<tr>
<td>Tyrell, Gregory</td>
<td>SP28, P32, P33</td>
</tr>
<tr>
<td>Tyson, John</td>
<td>P28, B03</td>
</tr>
<tr>
<td>Ugartel Torres, Alejandra</td>
<td>C03, P25, P74</td>
</tr>
<tr>
<td>Ulloa-Gutierrez, Rolando</td>
<td>P78</td>
</tr>
<tr>
<td>Unger, Sharon</td>
<td>SP08</td>
</tr>
<tr>
<td>Vaisman, Alon</td>
<td>SP76</td>
</tr>
<tr>
<td>Vallières, Emilie</td>
<td>E03, P38</td>
</tr>
<tr>
<td>Vancol-Fable, Fabiola</td>
<td>SP11, SP46</td>
</tr>
<tr>
<td>Vanner, Stephen</td>
<td>SP27</td>
</tr>
<tr>
<td>Varshney, Karan</td>
<td>SP02</td>
</tr>
<tr>
<td>Vaudry, Wendy</td>
<td>SP02</td>
</tr>
<tr>
<td>Vayalumkal, Joseph</td>
<td>D04, P23, SP46, SP13</td>
</tr>
<tr>
<td>Vegdani, Tasnim</td>
<td>P68, P69</td>
</tr>
<tr>
<td>Velapatino, Billie</td>
<td>B02</td>
</tr>
<tr>
<td>Vermeiren, Christie</td>
<td>P13</td>
</tr>
<tr>
<td>Viel-Thériault, Isabelle</td>
<td>C04, P74</td>
</tr>
<tr>
<td>Wada, Ray</td>
<td>P24</td>
</tr>
<tr>
<td>Wang, Bing</td>
<td>P20</td>
</tr>
<tr>
<td>Webber, Duncan</td>
<td>SP03</td>
</tr>
<tr>
<td>Wei, Ziming</td>
<td>P17</td>
</tr>
<tr>
<td>Wett, Matthew</td>
<td>P04</td>
</tr>
<tr>
<td>Williams, David</td>
<td>B01, P16, P18, P19, P22, P30, P42, P48, SP34</td>
</tr>
<tr>
<td>Williams, Victoria</td>
<td>SP26</td>
</tr>
<tr>
<td>Willis, Lori</td>
<td>P24</td>
</tr>
<tr>
<td>Wilson, Evan</td>
<td>P01, P50</td>
</tr>
<tr>
<td>Wobenes, Wendel</td>
<td>SP47</td>
</tr>
<tr>
<td>Wong, Alice</td>
<td>D02, P43</td>
</tr>
<tr>
<td>Wong, Han</td>
<td>A03</td>
</tr>
<tr>
<td>Wong, Henry</td>
<td>SP28, SP50</td>
</tr>
<tr>
<td>Wou, Allan</td>
<td>P21</td>
</tr>
<tr>
<td>Wood, Heidi</td>
<td>P12, P58, SP03</td>
</tr>
<tr>
<td>Woodward, Kevin</td>
<td>P59</td>
</tr>
<tr>
<td>Wu, Ge</td>
<td>SP36</td>
</tr>
<tr>
<td>Wu, Julie</td>
<td>D01</td>
</tr>
<tr>
<td>Wu, Manhong</td>
<td>P53</td>
</tr>
<tr>
<td>Wu, Ying</td>
<td>SP41</td>
</tr>
<tr>
<td>Wuerz, Terence</td>
<td>P16, SP25</td>
</tr>
<tr>
<td>Xie, Jianling</td>
<td>SP41</td>
</tr>
<tr>
<td>Xie, Max</td>
<td>P63</td>
</tr>
<tr>
<td>Yamamura, Deborah</td>
<td>SP49</td>
</tr>
<tr>
<td>Yau, Yvonne</td>
<td>P55, P78</td>
</tr>
<tr>
<td>Yee, Noelle</td>
<td>SP20</td>
</tr>
<tr>
<td>Yeh, E.</td>
<td>P74</td>
</tr>
<tr>
<td>Yeung, Eugene</td>
<td>P10, SP06</td>
</tr>
<tr>
<td>Yeung, Roseanne</td>
<td>P28, P29, P32, P31, P33, P52, P71</td>
</tr>
<tr>
<td>Yip, Bryan</td>
<td>P36</td>
</tr>
<tr>
<td>Yok-Corales, Adriana</td>
<td>P34</td>
</tr>
<tr>
<td>Yousfi, Khadija</td>
<td>P56, SP39</td>
</tr>
<tr>
<td>Yu, Yang</td>
<td>SP17</td>
</tr>
<tr>
<td>Zabariadis, George</td>
<td>P05, SP17</td>
</tr>
<tr>
<td>Zelyas, Nathan</td>
<td>P44, P66</td>
</tr>
<tr>
<td>Zhanel, George</td>
<td>P30, P42, P48, SP34</td>
</tr>
<tr>
<td>Zhuo, Ran</td>
<td>SP41</td>
</tr>
<tr>
<td>Zittermann, Sandra</td>
<td>SP26</td>
</tr>
<tr>
<td>Zvonar, Rosemary</td>
<td>P42</td>
</tr>
</tbody>
</table>
### CONFLICT OF INTEREST DECLARATIONS

<table>
<thead>
<tr>
<th>Full name</th>
<th>Role(s)</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alemayheu, Gelila</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Alsager, Khaled</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Behr, Marcel</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Benoit, Patrick</td>
<td>Oral Abstract Presenter</td>
<td>Grant: Roche</td>
</tr>
<tr>
<td>Bernachez, Isabelle</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Brabant-Kirwan, Danielle</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Burns, Laura</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Charles, Marthe</td>
<td>Scientific Planning Committee</td>
<td>Honoraria: Merck (MA-CanadianSMARTExpertInputForum2020)</td>
</tr>
<tr>
<td>Charlton, Carmen</td>
<td>Central Planning Committee</td>
<td>Grant: Merck (Investigator Initiated)</td>
</tr>
<tr>
<td>Chagla, Zain</td>
<td>Co-developed presentation speaker</td>
<td>Advisory Board: GSK, Merck; Grant: Roche</td>
</tr>
<tr>
<td>Connors, William</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Di Quinzio, Melanie</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Dingle, Tanis</td>
<td>Central Planning Committee</td>
<td>Grant: BioMerieux, Amplyx, Avir Pharma, F2G and JMI laboratories (Investigator)</td>
</tr>
<tr>
<td>Du, Tim</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Fattouh, Ramzi</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Ferris, Dwight</td>
<td>Sponsorship Committee</td>
<td>Advisory Board: Abbvie and Gilead; Honoraria: Gilead, Merck, Abbvie, GSK, ViiV and Verity</td>
</tr>
<tr>
<td>Forgie, Sarah</td>
<td>Central Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Fuller, Jeff</td>
<td>Central Planning Committee, Sponsorship Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Goldfarb, David</td>
<td>Speaker</td>
<td>Grant: BioMerieux, Perkin Elmer (Investigator)</td>
</tr>
<tr>
<td>Haider, Shariq</td>
<td>Central Planning Committee, Sponsorship Committee</td>
<td>Advisory Board: Merck, Pfizer, Takeda; Grants: AVIR Pharma, Verity Pharma, Merck, Takeda, Cidara Pharma</td>
</tr>
<tr>
<td>Hatchette, Todd</td>
<td>Central Planning Committee</td>
<td>Grant: GSK and Pizer (Investigator initiated for Severe Outcome Surveillance Network (SOS) of influenza and CAP in hospitalized adults (Shelly McNeil PI))</td>
</tr>
<tr>
<td>Hogan, Catherine</td>
<td>Scientific Planning Committee</td>
<td>Honoraria: Inflammatix</td>
</tr>
<tr>
<td>Jassem, Agatha</td>
<td>Central Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Full name</td>
<td>Role(s)</td>
<td>Disclosure</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Johnstone, Jennie</td>
<td>Scientific Planning Committee, Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Kandel, Christopher</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Khan, Farhan</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Khan, Kamran</td>
<td>Speaker</td>
<td>Founder/CEO: BlueDot</td>
</tr>
<tr>
<td>Kitai, Ian</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Kozak, Robert</td>
<td>Central Planning Committee, Scientific Planning Committee, Speaker</td>
<td>Honoraria: Chinese American Medical Society; Grant: GUARDRx, CANhealth</td>
</tr>
<tr>
<td>Krajden, Mel</td>
<td>Speaker</td>
<td>Grant: Roche, Hologic, Siemens and DiSorin</td>
</tr>
<tr>
<td>Labbé, Annie-Claude</td>
<td>Oral Abstract Presenter</td>
<td>Advisory Board: Merck, Pfizer</td>
</tr>
<tr>
<td>Lagacé-Wiens, Philippe</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Langley, Joanne</td>
<td>Speaker</td>
<td>Grant: Pfizer, Merck, GSK, Medicago, IMV, VBI, Vido-Intervac, Sanofi-Pasteur, Entos, Precision Nanosystems and Symvivo</td>
</tr>
<tr>
<td>Lavallée, Christian</td>
<td>Central Planning Committee</td>
<td>Advisory Board: Merck; Grant: Merck (Co-investigator)</td>
</tr>
<tr>
<td>Li, Lisa</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Lowe, Christopher</td>
<td>Central Planning Committee</td>
<td>Grant: Genome BC (Co-PI on the development of SARS-CoV-2 diagnostics(COV-115)); Merck (Investigator on development of a next-generation sequencing assay for CMV resistance); Canadian Liver Foundation (Co-I for assessing the prevalence of hepatitis B carriers in Greater Vancouver)</td>
</tr>
<tr>
<td>Macdonald, Noni</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Mak, Annie</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Malejczyk, Kathy</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>McAlpine, Alastair</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>McDonald, Emily</td>
<td>Co-developed presentation speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>McMullin, Kathleen</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Menzies, Dick</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Mertz, Dominik</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Miller, Matthew</td>
<td>Co-developed presentation speaker</td>
<td>Advisory Board: Seqirus; Grant: Medicago</td>
</tr>
<tr>
<td>Murthy, Srinivas</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Nagai, Esther</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Naus, Monika</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Parmar, Nidhi</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Full name</td>
<td>Role(s)</td>
<td>Disclosure</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Patel, Samir</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Patrick, David</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Patriquin, Glenn</td>
<td>Scientific Planning Committee, Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Pieroni, Peter</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Pinnell, Rhannan</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Poutanen, Susan</td>
<td>Central Planning Committee,</td>
<td>Honoraria: Merck; Advisory Board: Verity, Paladin Labs; Research Support: bioMerieux</td>
</tr>
<tr>
<td>Press, Natasha</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Reid, Emma</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Robinson, Joan</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Rubin, Earl</td>
<td>Scientific Planning Committee</td>
<td>Honoraria: GSK; Advisory Board: GSK, Pfizer, Novartis; Grants: MSD, Pfizer (Vaccine Trials)</td>
</tr>
<tr>
<td>Russell, Valentina</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Saeed, Sahar</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Salmon, Joanne</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Saxinger, Lynora</td>
<td>Co-developed presentation speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Schreiber, Yoko</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Schwartz, Kevin</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Sheth, Prameet</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Simor, Andrew</td>
<td>Central Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Smith, Stephanie</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Stephen, Craig</td>
<td>Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Strathdee, Steffanie</td>
<td>Speaker</td>
<td>Stocks: Adaptive Phage Therapeutics</td>
</tr>
<tr>
<td>Tran, Vanessa</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Turenne, Christine</td>
<td>Central Planning Committee,</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Ugarte Torres,</td>
<td>Oral Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Alejandra</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinh, Donald</td>
<td>Sponsorship Committee</td>
<td>Honoraria: CSL Behring Canada (Speaker. Site investigator for clinical trial. Principal investigator for clinical trial); Advisory Board: CSL Behring Canada, Avir Pharma, Merck Canada and Takeda; Grant: CSL Behring Canada, Cidara Therapeutics, Janssen Pharmaceutical</td>
</tr>
<tr>
<td>Weaver, Victoria</td>
<td>Members in Training Committee, Oral</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Wong, Titus</td>
<td>Abstract Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Yamamura, Deborah</td>
<td>Central Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
</tbody>
</table>
INDUSTRY CO-DEVELOPED PRESENTATIONS

These educational events are Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. These programs have been co-developed with AMMI Canada and are planned to achieve scientific integrity, objectivity and balance.

**The influenza vaccine (r)evolution**

**Moderator:** Philippe Lagacé-Wiens (Winnipeg, MB)

**Speaker:** Matthew Miller (Hamiton, ON)

By the end of the session the participants will be able to:

- Outline the main factors that impact annual influenza vaccine effectiveness
- Identify limitations in the use of randomized controlled trials to compare seasonal influenza vaccine efficacy
- Appreciate the need for real-world data related to influenza vaccines

**Strategic Deployment of COVID-19 Treatment Options: Who, What, Where and How?**

**Moderators:** William Connors (Vancouver, BC) Marthe Charles (Vancouver, BC)

**Speakers:** Lynora Saxinger (Edmonton, AB) Emily McDonald (Montreal, QC) Zain Chagla (Hamilton, ON)

By the end of the session the participants will be able to:

- Review risk factors for development and progression of COVID-19 and the impact of vaccination
- Discuss the use of therapeutics in outpatients with COVID-19, including how to deploy them and to whom
- Discuss the strategic use of therapeutics in inpatients with COVID-19

---

**Virtual participants are encouraged to take a “selfie” of themselves and submit their photos.**

Create a “Submit Photo” Button that links: cfid@researchid.com Participants will be eligible for prizes and photos will be collected so that a final montage of virtual walkers and runners can be posted on the CFID website. You are also encouraged to donate to the Bug Run (Create a “Donate” Button that links: https://www.researchid.com/support-us/donate-now/)

Our mandate – to improve the health of Canadians and people worldwide through the support of research and dissemination of knowledge pertaining to the prevention, diagnosis, control and treatment of infectious disease – has never been more relevant.
The Year in Clinical Virology – SARS-CoV-2 and Beyond

By the end of this session, participants should be able to:

• Discuss the latest developments in diagnostic virology

Speaker:
Benjamin Pinsky, MD, PhD
Medical Director, Clinical Virology Laboratory
Stanford Health Care and Stanford Children's Health
Medical Co-director, Point of Care Testing
Medical Director, Esoteric (send-out) Testing

Visit the PASCV booth in the Exhibit Hall for more details

COVID-19 and Long-Term Care – What does the future hold?

By the end of this session, participants should be able to:

• To review the history of COVID-19 in long term care in the pandemic today
• To describe the immunogenicity and effectiveness of mRNA vaccines in this population
• To discuss predictions for the 2020/21 winter

Speaker:
Allison McGeer, MD, FRCPC
Microbiologist, Infectious Disease Consultant
Department of Microbiology
Mount Sinai Hospital

Moderator:
Marlene Jantzi, RN, MPH, BScN, CIC
Liaison Section Chief, COVID-19 Response
Program Manager, Control of Infectious Diseases
Wellington-Dufferin-Guelph Public Health

Visit the Pfizer booth in the Exhibit Hall for more details
UNACCREDITED LEARNING ACTIVITIES

LIAISON XL® SARS-CoV-2 Serological Testing

Date: Monday, April 26
Time: 16:30 – 16:45 EDT
Location: Unaccredited Presentation Auditorium

With over 50 years of experience, DiaSorin is a global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and the molecular diagnostics segments. DiaSorin is continuing to aid in the COVID-19 pandemic response through innovative high-throughput and near patient testing solutions. The presentation will focus on a novel SARS-CoV-2 IgG assay that utilizes the full-length trimeric spike protein to detect immune response in a highly sensitive and specific manner.

Speaker:
Jeff Kormos, MSc., MBA
Corporate Vice President
DiaSorin

Visit the DiaSorin booth in the Exhibit Hall following the presentation for a question and answer session and for more information on DiaSorin

HOLOGIC®

OPENING UP THE WORLD OF MOLECULAR DIAGNOSTICS: More than STIs beyond the pandemic

Date: Tuesday, April 27
Time: 10:30 – 11:30 EDT
Location: Unaccredited Presentation Auditorium

Pre-registration required, maximum of 100 people

Technology and instrumentation capabilities in the field of molecular diagnostics has reached most Canadian labs through the course of 2020. Hologic will provide an overview of their Panther platform, walk you through the journey of STI testing up to emerging pathogens and open to possibilities to reach automation and consolidation beyond IVD testing through LDTs.

By the end of this session, participants should be able to:

- Understand there are overlapping symptoms of vaginal pathogens
- Learn about the possibilities beyond testing for STIs through open access without compromising automation and consolidation

Speakers:
Tyler Park
Director, Laboratory Marketing
Damon Getman
Director Scientific Affairs
Elenyah Klein
Senior Marketing Manager, Instrumentation

Visit the Hologic Inc. booth in the Exhibit Hall for more details

Unaccredited Learning Activities | 56
UNACCREDITED LEARNING ACTIVITIES

Evolving epidemiology and serotype distribution of invasive pneumococcal disease: what’s driving the ongoing clinical burden in Canada?

**Date:** Tuesday, April 27  
**Time:** 16:00 – 17:00 EDT  
**Location:** Unaccredited Presentation Auditorium  
**Pre-registration required, maximum of 100 people**

By the end of this session, participants should be able to:

- Review ongoing clinical burden and latest epidemiologic (serotype distribution) data for invasive pneumococcal disease in Canada: highlight national and regional trends
- Delineate key serotypes (both vaccine and non-vaccine types) of ongoing concern in context of existing pneumococcal immunization programs

**Speaker:**  
Angel Chu, MD, FRCPC, SPEC, COMP  
Assistant Professor  
Infectious Disease  
University of Calgary

Visit the Merck Canada booth in the Exhibit Hall for more details

---

Adding insult to injury: fungal infections complicating COVID-19

**Date:** Wednesday, April 28  
**Time:** 16:00 – 16:30 EDT  
**Location:** Unaccredited Presentation Auditorium  
**Pre-registration required, maximum of 25 people**

By the end of this session, participants should be able to:

- Review of COVID-Associated Pulmonary Aspergillosis’ (CAPA) pathophysiology and epidemiology
- Describe an algorithm to its diagnosis and management
- Provide an overview of interesting real-life cases

**Speaker:**  
Ilan Schwartz, MD PhD  
Assistant Professor  
University of Alberta

Visit the AVIR Canada booth in the Exhibit Hall for more details
The Antimicrobial Resistance Landscape in Canada and how we are tackling the problem

Date: Thursday, April 29
Time: 10:15 – 11:15 EDT
Location: Unaccredited Presentation Auditorium

This event will review Antimicrobial trends globally and in Canada, and describe the existing surveillance programmes, and opportunities to enhance surveillance. Furthermore, it will discuss the Pan Canadian Action Plan and barriers/enablers to roll it out and foster a One Health approach in Canada and globally.

By the end of this session, participants should be able to:

- Review AMR trends globally and nationally.
- Describe existing surveillance programmes and opportunities for enhanced surveillance
- Discuss the Pan Canadian Action Plan
- Discuss barriers and enablers to rolling out the action plan and fostering a One Health approach in Canada and globally.

Speakers:
Gerry Wright PhD
Director, Professor
Michael G. DeGroote Institute for Infectious Disease Research
Department of Biochemistry and Biomedical Sciences
Canada Research Chair in Antibiotic Biochemistry, McMaster University

Susan Poutanen MD, MPH, FRCPC
Associate Professor
Department of Laboratory Medicine & Pathobiology
Medical Microbiologist, University Health Network/Sinai Health Department of Microbiology
Infectious Disease Physician, University Health Network and Mount Sinai Hospital

Visit the Merck Canada booth in the Exhibit Hall for more details
UNACCREDITED LEARNING ACTIVITIES

SARS-CoV-2 Variants of Concern: What’s the Concern?

Date: Friday, April 30
Time: 11:00 – 12:00 EDT
Location: Unaccredited Presentation Auditorium

With the ongoing COVID-19 pandemic, challenges continually emerge for healthcare facilities. We will discuss the changing epidemiology of Variants of Concern (VoC) and the challenges to the laboratory response to the detection of these variants.

By the end of this session, participants should be able to:

- Describe the emerging epidemiology of SARS-CoV-2 variants of concern
- Outline laboratory approaches to the identification of SARS-CoV-2 variants of concern
- Discuss ongoing challenges the laboratory faces in response to SARS-CoV-2 variants of concern

Speakers:
Christopher Lowe MSc, MD, FRCPC  
Clinical Professor  
UBC Dept. of Pathology & Laboratory Medicine  
Medical Microbiologist, Providence Health

Nancy Matic MD  
Clinical Assistant Professor,  
UBC Dept. of Pathology & Laboratory Medicine  
Medical Microbiologist, Providence Health

Moderator:  
Caroline Vincent  
Medical Liaison  
Cardiology, Prenatal Care and Infectious Diseases

Visit the Roche Diagnostics booth in the Exhibit Hall for more details
EXHIBIT HALL

The annual conference has received tremendous support from our industry partners - be sure to visit the Exhibit Hall. You can access the booths, virtually on the platform by clicking on the company name found in the Exhibitors Index or by scrolling through the 3D exhibit hall.

Exhibit Hours

The Exhibit Hall will be available on demand during the conference and for one month post event. Dedicated times have been scheduled for booth representatives to be available for live 1:1 chats or via text chat on the platform.

Monday, April 26 16:00 - 18:00 EDT
Wednesday, April 28 15:45 - 18:00 EDT
Thursday, April 29 13:30 - 15:00 EDT
Friday, April 30 10:00 - 12:00 EDT

EXHIBITORS INDEX

Abbott Laboratories
Association of Medical Microbiology and Infectious Disease Canada
AVIR Pharma Inc.
Becton Dickinson Canada Inc.
Bio-Rad Laboratories
BioMérieux Canada, Inc.
Canadian Association of Clinical Microbiology and Infectious Diseases
Canadian Foundation for Infectious Diseases
DiaSorin Canada
Gilead Sciences Canada
Hologic Canada ULC
Horizon Health Network
Infectious Disease Society of America and IDWeek
Innovatek Medical
Inter Medico
Merck Canada Inc
Micronostyx
Nosotech
Pan American Society for Clinical Virology
Pfizer Canada Inc.
Pro-Lab Diagnostics Inc.
Public Health Physicians of Canada
Quidel Canada
Randox Laboratories
Roche Diagnostics
Seegene Canada Inc.
Seqirus Canada
Somagen Diagnostics Inc.
Thermo Fisher Scientific – Microbiology
Verity
SPONSORS

Merck
Gilead
Seqirus
Hologic
Roche
Pfizer Vaccines
AVIR Pharma
Bespoke Audio Visual
DiaSorin
Moderna
r-biopharm Clinical Canada

GENERAL INFORMATION

Conference Secretariat
192 Bank Street
Ottawa, ON K2P 1W8, Canada
Tel.: (613) 260-3233 ext. 105
Toll-free: 1 (888) 467-1215 ext. 105
meetings@ammi.ca
www.ammi.ca
www.cacmid.ca

Registration Information
Unconventional Planning
32 Colonnade Road, Unit 100
Ottawa, ON K2E 7J6, Canada
Tel.: (613) 721-7061
Toll-free: 1 (888) 625-8455
registration@unconventionalplanning.com